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ABSTRACT: AN EXAMINATION OF LUMBAR AND VENTRICULAR CEREBROSPINAL FLUID FINDINGS 
IN CHILDREN WITH TUBERCULOUS MENINGITIS AND HYDROCEPHALUS  
 
Background: Childhood tuberculous meningitis (TBM) has poor outcomes. These are often associated with delayed 
diagnosis because early diagnosis and treatment is challenging. Existing diagnostic criteria use CSF characteristics to 
suspect TBM. However, lumbar and ventricular CSF may differ. These differences have not been well characterised 
Sometimes only ventricular CSF is available and decisions about surgical treatment may be influenced by CSF 
characteristics. This study examined CSF parameters from lumbar and ventricular compartments in patients with TBM 
and hydrocephalus who required neurosurgical procedures, their CSF temporal profiles, differentials between 
compartments, and factors that may influence these results. 
Methodology: A descriptive cross-sectional study was conducted including data from two prospective TBM studies. 
Children treated for TBM and hydrocephalus at Red Cross War Memorial Children’s Hospital with lumbar and/ or 
ventricular samples were selected. Pooled lumbar verses ventricular samples and paired time-linked samples in 
individual patients were analysed. Differences in CSF cell counts and biochemistry parameters across compartments 
were analyzed using Wilcoxon signed rank test, and temporal profiles graphically presented. Associations between 
laboratory, clinical and radiological data were analyzed using Mann-Whitney’s U test. To test for associated factors, 
results of the nature of hydrocephalus (level of CSF obstruction) and spinal imaging were analyzed where available. 
Association between CSF parameters and morbidity was analyzed. 
Results: Eighty-one patients were studied, 29 had time-linked paired CSF. The mean patient age was 36 months (2-
156 months), 93% were HIV-uninfected, and the mortality rate was 13.6%.  Seventy-two percent had communicating 
hydrocephalus, 16% non-communicating, and 12% uncertain (unable to demonstrate level of block). Medians of 
admission lumbar CSF showed low glucose (2.2 mmol/L), low chloride (112 mmol/L), raised protein (2g/L) and 
elevated white cell count (165 x 106/L). Corresponding values for admission ventricular CSF were minimally affected 
glucose (3mmol/L), mildly low to normal chloride (114.5mmol/L), normal to mildly raised protein (0.5g/L) and less 
elevated white cell count (22 x 106/L). In paired samples, all parameters were significantly different between lumbar 
and ventricular CSF. Ventricular CSF showed milder aberrations than lumbar CSF: lower protein and total white cell 
count, higher glucose and chloride. All paired samples showed higher lumbar CSF protein; lower lumbar CSF chloride 
in almost 80%; lower lumbar CSF glucose in 96%. Analysis of possible factors was limited by the small patient 
numbers who had full brain and spine imaging, and also paired CSF samples (n=17). However, maximum lumbar CSF 
protein was associated with severity of spinal disease on imaging. The lymphocyte ratio between lumbar and 
ventricular CSF was higher in patients with non-communicating and uncertain hydrocephalus. CSF parameters 
normalized slowly. White cell count and lymphocyte CSF differential were associated with favorable outcome in 
survivors. 
Conclusion: Lumbar CSF depicted a typical TBM pattern. Ventricular CSF differed: CSF parameters were less 
abnormal in both pooled analysis and across individual paired samples. Spinal disease severity and nature of 
hydrocephalus may affect this differential. The CSF compartment sampled is therefore clinically relevant when 
interpreting CSF characteristics for diagnostic and treatment decisions. Studies of TBM diagnosis, pathophysiology, 
biomarkers and drug concentrations should consider these differences.  
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CHAPTER 1: BACKGROUND OF PAEDIATRIC TBM   
 
1.1 Literature search strategy 
A literature review of the subject was conducted with English articles identified using PubMed, 
ClinicalKey, SCOPUS, EBSCO Host and Google Scholar. There were no time limits set due to the known 
paucity of published literature on paediatric TBM.  
Keywords used to search the literature included ‘TB, tuberculo*, mycobact*’; ‘Mening*, CNS, neur*, 
brain, nerv*’; ‘Spin*, myelo*, myeli*’; ‘Arachnoid*’; ‘Lumba*’; ‘ventric*’; ‘CSF, cerebrospinal’. 
SCOPUS and Google Scholar keyword search terms included “TB”, “tuberculous”, “tuberculosis”; 
“Meningitis”, “CNS infection”, “neurotuberculosis”; “arachnoiditis”; “CSF”, “cerebrospinal fluid”. 
After exclusions for relevance, a total of 90 articles were reviewed. 
 
1.2 The scope of the problem 
Tuberculous meningitis (TBM) is responsible for 10% of tuberculosis (TB) cases in children, but is the 
most severe and lethal form of the disease (1–6). Children generally contract TB from an adult infected 
contact (3,5,7,8), and most cases (82%) occur under the age of 5 years (3). Despite treatment with 
antituberculous drugs and steroids, the disease has a high mortality (13%–50%) and high morbidity with 
poor neurological outcomes are common (50%) (3,5,9–12). Early commencement of anti-TBM treatment 
and steroids improves the odds of a good outcome (3,5,13), but delayed treatment often increases mortality 
(14). 
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1.3 Aetiology and Pathophysiology of TBM 
TB is a granulomatous disease affecting multiple organ systems caused by Mycobacterium tuberculosis 
(Mtb) (6). TB granulomas are organised structures that form as a result of the cell mediated immunity to 
contain Mtb infected macrophages. Central nervous system (CNS) TB may occur individually as TBM, 
tuberculomas or tuberculous abscesses of the brain, TB of the spinal cord, TB of the bony spine, or together 
(2,15–18).   
 
A “two step model” for the pathogenesis of TBM has been proposed (5,17,19). It has been suggested that 
Mtb spreads from a primary focus in the lungs via the lymphohematogenous route and crosses the blood 
brain barrier to form Rich foci (caseous granulomas/ tuberculomas) in the meninges and/or sub-pial area of 
the brain (19). The Rich focus then ruptures, releasing Mtb into the cerebrospinal fluid (CSF)-filled 
subarachnoid space surrounding the brain and spinal cord (3,20,21). Subsequently, this may progress to 
new tuberculomas developing, an inflammatory response of the meninges surrounding the brain and spinal 
cord, and thick inflammatory exudate in the basal cisterns that cause  obstruction to CSF flow and vasculitis-
induced brain infarction (3,6,21,22). 
 
Varying descriptions for “TB spine” across literature include TB of the central nervous system, such as 
arachnoiditis (radiculomyelitis), intramedullary spinal cord tuberculomas, epidural phlegmon and TB spinal 
abscess, as well as involvement of the spinal column, such as TB discitis and TB infection of the vertebral 
bones (15,17,18,23).  TB spondyloarthritis, described as spinal disease involving the spinal column and 
cord, occurs in 1%  (18,23) and is a leading cause of paraplegia in developing countries (15,23,24). This 
MMed project excludes vertebral column bony involvement to focus on primary CNS involvement; TB 
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spine in this context refers to spinal involvement as subarachnoid and parenchymal involvement of the 
spinal nervous system. 
 
TB arachnoiditis is thought to arise from haematogenous dissemination of Mtb seeding to the brain and 
spinal cord. It may occur primarily or develop secondary to vertebral or intracranial TB infection (15,17,25).  
TB spinal arachnoiditis may occur paradoxically following commencement of anti-TBM treatment, or 
evolve despite treatment (18), resulting in the formation of exudate, tuberculomas, abscesses, adhesions, 
and infarction or compression of the spinal cord (15,18). Symptomatic patients develop fever (70%), 
paraplegia (60%) or paraparesis (30%), monoparesis (10%), urinary retention (50%), and/or bowel 
incontinence (20%) (15). In one study, patients with spinal arachnoiditis more likely had a dry spinal tap 
(16).  
 
1.4 Epidemiology of TBM in the Western Cape region of South Africa  
TB is a global challenge: 10 million individuals develop TBM out of 2 to 3 billion infected with Mtb 
worldwide (3,14,26–28), up to 87% of which occurs in developing countries (27,29). The WHO Global TB 
Report (2018) (27) records that children accounted for 1 million of those newly infected with TB and 
230,000 of the 1.6 million TB deaths. South Africa (SA) is amongst the hardest hit by TB worldwide, with 
an incidence of  567  (406 to 754) per 100,000 in 2017 (27). The Western Cape Province, where this MMed 
study was conducted, has had the highest incidence of TB in the country (26,30). TBM is the commonest 
cause of bacterial meningitis in adults and children (26,31) in the Western Cape. This has been influenced 
by the HIV pandemic and the successful reduction in other previously common causes of pediatric bacterial 
meningitis following an introduction of routine H. Influenzae B (Hib) and Pneumococcal vaccines (PCV) 
under the Extended Programme of Immunization (EPI) (31). The incidence of TBM varies with age; there 
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is a peak in infants (<12 months old) which decreases through to pre-adolescents and teens (3,6,21,22). A 
Western Cape study of paediatric TBM (3) recorded the following: most children were under 5 years old 
(82%), most were HIV negative (96%), and most had received routine BCG vaccine (97%). Almost half 
(47%) did not have a known TB contact. In a study by Rohlwink et al. (32) at RCWMCH results were 
similar:  84% were under 5 years old, 95% were HIV negative, but only 79% children were immunized 
with BCG. Their study had a high rate of CSF culture positivity (56%), which is higher than commonly 
reported, presumably because of larger amounts of CSF that were sent for culture. All cases were TB drug 
sensitive. Only 48% of patients had a recent positive TB contact. Half of the cohort (52%) had chest x-ray 
(CXR) findings suggestive of pulmonary TB, and most (76%) showed radiological evidence of concurrent 
TB spinal disease on spinal MRI, the vast majority of which was clinically asymptomatic. The authors 
identified subsets of pediatric spinal disease as extramedullary intradural plaque-like collections of exudate 
(9%), spinal tuberculomas (18%) and spinal arachnoiditis (72%) and no occurrence of vertebral TB. At the 
hospital, 24 children on average were admitted yearly with definite or probable TBM, with a mortality rate 
of 13.5% (32). Hydrocephalus with associated raised intracranial pressure (ICP) occurred in 72% of these 
children. Hydrocephalus signifies more severe TBM disease and is classified into two forms, namely 
communicating (where the block to CSF flow is in the basal cisterns and CSF in the ventricles 
communicates with CSF in the cisterns) and non-communicating (where there is a block to CSF egress 
from the ventricular system). The institutional protocol involves surgical treatment of non-communicating 
hydrocephalus in the first instance, and medical treatment (with or without temporary ventricular drainage) 
in the first instance for communicating hydrocephalus, with shunt surgery reserved for failed cases (33–
35).  
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1.5 Clinical presentation and evaluation in TBM 
In children, TBM disease often develops within 2 – 6 months of a primary pulmonary TB infection (14). 
Common non-specific symptoms are cough, lethargy, apathy, restlessness, personality changes, inability to 
play, headaches, loss of appetite, nausea, diarrhoea, vomiting, fever and seizures  (3,11,13,36). A clinical 
TBM staging system is routinely used by clinicians on admission and follow-up. It describes the range of 
neurological clinical signs exhibited on presentation depending upon severity of TBM disease and its 
impact on the CNS (3,10,11,37). Typical clinical neurological signs are depressed level of consciousness, 
cranial nerve palsies and other focal motor deficits, and abnormal movements; symptoms have usually been 
present for more than 6 days (38). Over time, several TBM severity grading systems have been developed 
for clinical use in children and adults across different resource settings, including the British Medical 
Research Council (MRC) staging system (39), the Vellore Grading System (40,41), the Tygerberg 
Children’s Hospital Scale (37), Acute Physiology and Chronic Health Evaluation II score (42), and TBM 
Acute Neurological Score (43). Of these, the British MRC system has been most widely used  (37). The 
original MRC staging system has undergone revisions to improve its effectiveness and application. The 
Revised TBM Medical Research Council (MRC) Scale (37) outlines four clinical stages (Appendix 1). 
When re-applied 1 week after admission, it is a good predictor of neurological outcome. The rationale for 
repeating staging after 1 week was to allow for resolution of any contributing secondary reversible clinical 
factors which are potentially treatable, such as hyponatremia, medications or seizures, which might give 
poorer staging on admission (32,37,44). Children with Stage 1 TBM have a normal level of consciousness 
(Glasgow Coma Scale [GCS] 15/15) and no focal neurological signs.  Patients in Stage 2a TBM are alert 
(GCS 15) with a neurological deficit, or have a mild alternation of consciousness (GCS 13–14) with or 
without a focal neurological deficit. In stage 2b, children show moderate altered levels of consciousness 
(GCS 10-12) with/ without focal neurological deficits. Stage 3 TBM describes advanced disease with 
significantly depressed consciousness (GCS < 10) with/ without focal neurological deficits.  
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1.6 Important complications of TBM   
Complications of TBM include hydrocephalus and raised intracranial pressure, cerebral ischemia and 
infarcts, hyponatremia, seizures, tuberculomas, and TB brain abscesses (5,6,17,38,44,45). Rare 
complications include mycotic cerebral vessel aneurysms, venous sinus thrombosis (5) and secondary 
bleeds (22,46). Most complications occur within the initial 3 months of anti-TBM treatment and contribute 
to poor clinical outcomes (5,6,45).  
 
Hydrocephalus is a known factor independently contributing to poor outcome in TBM and is seen in the 
more severe spectrum of the disease (3,6,13,45). It occurs in 80-85% of TBM cases (5,6,44,47) and presents 
a life threatening neurosurgical emergency. It is more common in children (6,40,45). Two key mechanisms 
are described: tuberculous exudate in the basal subarachnoid space blocks cisternal CSF flow and may 
reduce absorption by the brain and arachnoid granulations (communicating hydrocephalus, approximately 
80-85% of cases) and/or obstructs CSF flow at the outlet foramina of the fourth ventricle or cerebral 
aqueduct (non-communicating hydrocephalus, 15-20%) (6,45). The resultant rise in intracranial pressure 
reduces cerebral perfusion pressure and may reduce cerebral blood flow, increasing the risk of ischaemia. 
Hydrocephalus may also develop later when formation of scar tissue obstructs CSF outflow from the fourth 
ventricle (3,6,40). Currently available brain imaging techniques using MRI or CT cannot reliably 
differentiate between the two types of hydrocephalus (3,33,40,45,48). In older children, TBM 
hydrocephalus may show a 4-6 week delayed onset in contrast to children under 12 months old where it 
may present acutely within 5-10 days of the onset of TBM disease (6). A high index of suspicion is required 
by the attending clinician to seek urgent brain imaging and neurosurgical opinion regarding treatment 
options (44,45). Illustration 1 depicting the process of hydrocephalus is shown below. 
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Illustration 1: CSF Flow and Hydrocephalus in TBM 
 
  
This illustration depicts brain, spinal cord, CSF flow and common points of CSF obstruction leading to hydrocephalus in TBM.  
Hydrocephalus causes increased ventricular size. CSF flows from the lateral ventricles (A) through their foramen, through the 
3rd ventricle and the Aqueduct of Sylvius (B), into the 4th ventricle and it’s foramen (C), which open into the Cisterns (pools of 
CSF) (D). (E) is the intracranial subarachnoid space. The spinal subarachnoid space (F) contains CSF, but may demonstrate a dry 
lumbar tap with the occurrence of spinal block. Subarachnoid granulations (G) absorb CSF into the venous sinus system. The 
skull (H), brain parenchyma (I) and spinal cord (J) are shown. Choroid plexus within the ventricles (K) produces CSF. CSF 
obstruction at points 1 and 2 cause non communicating hydrocephalus; and at 3 communicating hydrocephalus. Source of 
diagram: Author. 
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Other potential mechanisms that may increase intracranial pressure include cerebral oedema and 
obstruction of venous sinuses/ deep venous drainage of the brain.  
 
Brain ischemia occurs due to compromised blood supply to the brain as a result of vasculitis and raised 
intracranial pressure. The middle cerebral artery and its perforators is most commonly involved (49,50). 
Reduced blood flow leads to brain infarction in 13% to 60% cases (16,49,50); infarction is associated with 
high  mortality (5,6,22,49). Loss of autoregulatory capacity and brain oedema secondary to the injury may 
adversely contribute to the sequence of events.  Common morbidities resulting from brain infarction include 
hemiplegia, spastic quadriplegia and cranial nerve palsies (5,22).  
 
TB granulomas (tuberculomas) are focal space-occupying lesions that may develop in the parenchyma of 
the brain and spinal cord, subpial locations, or cisterns. As a result of mass effect and the underlying reaction 
of the brain, they may cause seizures and focal neurological deficits. Rarely, large intracranial tuberculomas 
or tuberculous abscesses may cause brain shift and reduced level of consciousness. Spinal cord 
tuberculomas may present with spinal cord compression and arm, leg, and even respiratory weakness (6). 
On CT or MRI scan with contrast, tuberculomas appear as ring-enhancing lesions with a variety of signal 
characteristics depending upon the histological stage of the lesion (5,6,18).  
 
Hyponatremia occurs in 85% of pediatric TBM cases (44). The two causative mechanisms described are 
cerebral salt wasting and Syndrome of Inappropriate Anti-Diuretic Hormone secretion (SIADH) (44,45). 
The low serum osmolality accompanying hyponatremia may cause seizures and exacerbate brain oedema. 
An association has been suggested between presence of hyponatremia and worse outcome (45).  
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Rarely, TB abscesses form within the brain or spinal cord (6,44,51). They account for 0.5% of TB 
intracranial lesions and although they have suggestive imaging characteristics, occasionally they may be 
difficult to differentiate from tuberculomas, neoplasms, or other forms of intracranial abscesses (2). They 
have an outer capsule surrounding a liquefied caseating centre containing viable mycobacteria (6). Despite 
the start of anti-tuberculous therapy, they may progress in size and require surgical drainage. However, 
most resolve well with TBM treatment and steroids and surgical drainage or excision where needed 
(2,6,51). Alternative treatments such as thalidomide have been reported (52,53). 
 
1.7 Clinical outcomes in children 
TBM is associated with devastating consequences to the child and family (3,6,47). Even when appropriate 
TBM treatment is commenced or completed, poor outcomes are common (21,54). Although the results of 
the series by Van Well et al. (3)were relatively good compared to other series, still 13% of their cohort died 
and 71% were left with neurological sequelae. Similarly, Chiang et al. (54) reported that only around a third 
of patients survived without neurological sequelae.  More severe pediatric TBM disease at presentation was 
associated with a higher occurrence of permanent neurological morbidity (3,37), exacerbated by cerebral 
vasculitis, infarcts, hyponatremia, raised intracranial pressure, and co-infection with HIV (3,37,45). 
Although treatment with steroids reduces mortality, it does not reduce long-term neurological sequelae in 
survivors. 
 
Delayed diagnosis and treatment lead to poorer TBM outcomes (3,5,49,55). Approximately 20% of children 
with TBM die while receiving anti-TBM treatment (56). The Revised MRC Scale applied 1 week after 
admission was shown to be an effective prognostication tool and was able to predict neurological outcome 
in 84% of cases who completed the standard 6 months of anti-TBM treatment. Patients who score worse 
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are more likely to have long term impaired CNS function and lower developmental quotient (37). Adverse 
outcomes include intellectual impairment (77%), motor deficits (44%), impaired hearing (16%) impaired 
vision (14%) and cerebral palsy (3,37).  
1.8 Diagnosis 
Pediatric TBM may be a diagnostic dilemma, often because the clinical presenting symptoms are non-
specific (5,38,44,57). Prodromal symptoms (fever, vomiting, listlessness, headache, general ill health) may 
appear similar to a flu-like illness (44) and are easily overlooked, thus increasing the risk of diagnostic 
delay and progressive brain injury (3,6). Being typically a sub-acute meningitis, TBM may lack the classical 
feature of neck stiffness expected in meningitis (44). Consequently, almost 60% of children present with 
non-specific symptoms of greater than one week duration (3). Sometimes the diagnosis on CSF cannot be 
distinguished from viral or partially treated bacterial meningitis (3,58). Furthermore, approximately half of 
children have no known TB contacts (3). Although 57% of children with TBM also have PTB (12), sputum-
based diagnosis has a low yield (8). 
 
Given these difficulties, clinicians must have a raised awareness and a high index of suspicion for TBM 
(58), especially in endemic areas. Treatment delay proves the strongest risk factor for death (5,13,21). 
Sensitive, rapid and affordable methods for testing TBM are not readily available in resource-limited 
settings (4,59,60) and more needs to be done to develop better diagnostic approaches (5,47).   
 
A positive microbiology identification of Mtb in CSF culture or Ziehl-Neelsen staining is the gold standard 
diagnostic test (57). However, the probability of culturing Mtb from CSF is often poor, owing to the 
paucibacillary nature of CSF in TBM (20,57,61), with only a 12% positive yield (3) requiring prolonged 
culture times of 14 to 42 days (57), although Rohlwink et al. (32) reported a higher culture positivity rate 
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of greater than 50%. CSF TB culture results have been regarded as too insensitive and slow to aid immediate 
clinical decision making (5,57,59,62), and function better as a ‘rule-in’ test rather than a ‘rule-out’ test 
(63,64). Alternative diagnostic tests have been investigated. Mtb DNA PCR methods have a sensitivity 
range of 33% to 90%, and specificity of 88% to 100% (65) but tend to be costly (29). Mtb DNA PCR testing 
methods such as Gene Xpert Mtb/RIF (Cepheid, USA) was originally developed and validated on sputum. 
Initial validation studies for use in CSF samples indicated lower sensitivity than CSF microbiological 
methods (60). Some recent evaluations show improvement in diagnostic sensitivity of GeneXpert as high 
as 72-88% in definite TBM cases (64,66). Further research into laboratory diagnosis of TBM are needed 
(63,64,66,67). Global TBM experts, including the WHO, recently provided strong recommendations for 
use of Gene Xpert testing on CSF as a useful initial, rapid diagnostic tool despite its limitations (57,64). 
Gene Xpert showed a sensitivity of 79.5% (62-90.2%) against a culture reference gold standard, and 55% 
against a clinical gold standard in a 2013 WHO pooled meta-analysis (57). Few studies have been conducted 
on nucleic acid amplification testing (NAAT) in pediatric TBM (62). Cost-benefit analysis studies on the 
use of NAAT for TBM diagnosis in resource limited settings are lacking. 
 
A diagnosis of ‘probable TBM’ hinges upon a combination of clinical features, radiological features and 
CSF chemistry (4). Appendix 2 illustrates the Marais et al. (4) diagnostic criteria derived as a research tool 
to standardise TBM diagnoses across studies.  A classical TBM CSF picture is characterized by lymphocyte 
predominance with less than 50% neutrophils; leukocyte counts of less than 500 x 106/L (50-1000 x 106/L); 
increased protein (0.5 – 2.5g/L or more); and low glucose (95% cases demonstrate a CSF to plasma glucose 
ratio less than 0.5) (4,38,63,68). However, deviations from this classical pattern may occur (1,3,5,65). Van 
Well et al. (3) reported, based on initial CSF results at presentation, that up to 11% of children with TBM 
were incorrectly treated as bacterial meningitis. Eighteen percent of cases presented with a CSF picture that 
might be misdiagnosed as viral meningitis because of lymphocyte predominance, relatively low cell count 
less than 400 – 500 x 106/L and relatively low protein less than 0.8g/L (69). Fungal meningitis and partially 
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treated bacterial meningitis could prove challenging to differentiate from TBM based on CSF parameters, 
particularly in early TBM stages when neutrophil predominance up to 36% may prevail confounding the 
diagnosis. Furthermore, in early TBM, CSF protein levels may still be low (29). A slow decrement in CSF 
abnormalities may help - pleocytosis and raised protein were found to persist longer in TBM (56 – 92 days) 
than in other forms of meningitis whose parameters normalized quickly (69–71). Serial lumbar punctures 
for CSF investigations may thus be helpful to distinguish TBM from other forms of meningitis. Schoeman 
et al. (70) highlighted the importance of understanding serial CSF changes over time during TBM treatment 
for clinical decision-making. They observed in their study of 131 children with TBM that a transient 
deterioration in lumbar CSF parameters during the early weeks of TBM treatment may occur and does not 
necessarily indicate incorrect TBM diagnosis or inappropriate treatment for TBM. 
 
Contrasted brain CT scans (or MRI) are essential in the early radiological diagnosis of TBM. Radiological 
features include hydrocephalus (70-85%), pre-contrast hyperdensity in the cisterns (65.9%), basal 
meningeal enhancement (96%), infarcts (65.9%), tuberculomas (59%) (3,6,16). MRI spine is important in 
investigating TB spine. Spinal involvement has been reported in 76% of paediatric TBM patients, and 
included spinal tuberculomas (18%), enhancement of spinal cord meninges and nerve roots (spinal 
arachnoiditis, 73%) (16). Wasay et al. (15) and Rohlwink et al.  (16) describe similar occurrence of spinal 
arachnoiditis in TBM (70% in adults and 72% in children respectively). Clues from CSF such as rising or 
very high protein values or a dry lumbar puncture tap (four-fold risk) are suggestive of TB arachnoiditis 
(16,18).   
 
An absence of typically expected TBM radiological features on spinal imaging may not exclude TB myelitis 
(15). Vertebral lesions were not found in children presenting with TBM (16). 
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1.9 Parameters for treating TBM at Red Cross War Memorial Children’s Hospital (RCWMCH) 
Typically at RCWMCH, the decision to treat a patient for TBM is based on clinical judgment supported by 
a suggestive history, physical examination and laboratory/ imaging results. Suspected cases are started on 
four drug anti-TBM treatment (Rifampicin, Isoniazid, Pyrazinamide, Ethionamide) and steroids 
(Prednisolone). If there is evidence of pulmonary TB and not TBM, treatment would be down scaled to 3 
drug pulmonary TB treatment. The parameters illustrating this clinical decision-making process are outlined 
in Appendix 3 based on the clinical protocols used at RCWMCH. Patients with hydrocephalus undergo 
lumbar air encephalography (5,33) and/or a CSF column test if an external ventricular drain (EVD) has 
been inserted (34) to establish whether the hydrocephalus is communicating or not. If the patient is acutely 
unstable with signs of raised ICP a temporary EVD is inserted before lumbar puncture and air 
encephalography. Non-communicating hydrocephalus is treated with a ventriculo-peritoneal shunt (VPS) 
or endoscopic third ventriculostomy (ETV) (33,34). Communicating hydrocephalus is medically treated in 
the first instance, with serial lumbar punctures in addition to Acetazolamide and Furosemide for 3-4 weeks 
or until the ICP normalises. Failed medical cases (progressive hydrocephalus and/or persistent increased 
intracranial pressure) undergo ventriculoperitoneal shunt insertion. Figaji & Fieggen (34) summarized the 
current treatment algorithm for raised intracranial pressure in pediatric TBM (Appendix 4). 
 
1.10 Ventricular and lumbar CSF compartments in CNS infection 
1.10.1 Comparisons between Ventricular and Lumbar CSF Compartments 
Normal CSF flow is thought classically to follow a rostro-caudal direction in a pulsatile manner, although 
various theories of normal and abnormal CSF circulation have been proposed. A rostro-caudal gradient 
between ventricular and lumbar compartments of various CSF components, specifically protein, leucocytes 
and glucose is described in central nervous system (CNS) infection. Literature describing lumbar and 
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ventricular CSF compartments in TBM is scarce. Some data is available for bacterial meningitis. Gerber et 
al. (72) drew results from paired lumbar and ventricular CSF samples of a large patient cohort diagnosed 
with community acquired and post-neurosurgery acute bacterial meningitis. They demonstrated higher 
leukocyte counts in the lumbar CSF compared to ventricular CSF. This differential was attributed to 
inflammatory mechanisms mounted in response to meningeal infection that lead to an increased 
permeability of the blood-brain-barrier and blood-CSF barrier especially at the region of the CSF space 
with maximal inflammation. More importantly, it was noted that the wide variation in protein and leukocyte 
concentrations between lumbar and ventricular CSF in meningitis meant that the values of these two 
parameters could not be predicted for one compartment based on CSF samples taken from the other 
compartment. Naija et al. (73) described rostro-caudal gradients of analytes in paired ventricular and lumbar 
CSF samples in post-neurosurgical bacterial meningitis. Protein and leucocytes were higher and glucose 
lower in lumbar versus ventricular CSF samples. This differential was more marked during the acute stage 
of meningitis. They postulated that in human meningitis this differential picture reflects compartmentalized 
inflammation with more meningeal inflammation occurring in the lumbar than ventricular region. Torres-
Corzo et al. (17) studied paired lumbar and ventricular CSF samples in patients with hydrocephalus 
secondary to neurocysticercosis. They too found a rostro-caudal gradient of protein and polymorphs with 
significantly higher levels in lumbar CSF. There was no significant difference between glucose levels in 
the two CSF compartments.  
 
A study in adult TBM demonstrated a differential in Mtb bacteriological yields from CSF sampled in 
different CSF compartments: the cisternal CSF contained the highest yield (87.5%) when compared to 
ventricular CSF (75%) and lumbar CSF (11.5%) using standard Mtb microbiological methods (74). Normal 
ventricular CSF may not necessarily rule out TBM (75); therefore, lumbar CSF samples should be obtained 
for testing where TBM is suspected despite negative ventricular CSF findings. In TBM the cumulative 
addition of immune proteins and leukocytes as the CSF flows down the brain-spine axis may be increased 
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by arachnoiditis in the spinal canal which may hamper the CSF flow and lead to pooling in the lumbar 
space as described with spinal block in Froin’s syndrome (76). Froin’s syndrome is described as 
xanthrochromic (yellow tinged) and easily coagulable CSF resulting from raised CSF protein content from 
meningeal inflammation or blockage of CSF flow by tumours or spinal abscesses. Restricted CSF flow in 
the caudal spinal space is known to increase CSF protein. Therefore, lumbar CSF may reflect a combination 
of intracranial disease, intraspinal disease, and restricted flow (16).    
Recently, Kamat et al. (77) reported surprising findings on lumbar and ventricular CSF: in their study there 
were no statistically significant differences between lumbar and ventricular CSF protein, contrary to 
expectation. CSF protein was remarkably similar in ventricular and lumbar CSF samples (2.471 g/L and 
2.474 g/L respectively). With no differences between adults and children noted. No comment was made on 
other CSF parameters. The authors suggest that lumbar CSF protein levels can be used to predict ventricular 
CSF protein, the level of which should be a guide to whether a shunt should be placed or not, given their 
observation that patients with higher protein levels had an increased risk of shunt blockage. However, there 
are other studies that suggest differences between lumbar and ventricular CSF (78,79) and these differences 
would have important clinical implications for diagnosis and treatment; therefore further clarity is needed.  
 
1.10.2 Temporal profiles of CSF parameters within the lumbar and ventricular compartments 
There is little written about the temporal changes in ventricular and lumbar CSF parameters in TBM. 
Knowing these patterns of CSF cell count and biochemistry parameters and how they change in response 
to TBM treatment may help clinical decision-making (70,80). Where the diagnosis of TBM is in doubt, 
follow-up lumbar punctures to observe for CSF changes while on empirical TBM treatment may assist in 
strengthening the diagnosis of TBM and gauging the appropriateness of TBM treatment based on the typical 
treatment response.  
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Donald et al. (69) studied lumbar CSF changes over time in 99 children treated for TBM at Tygerberg 
Children’s Hospital, Cape Town. No children were treated with adjuvant corticosteroids. Serial lumbar 
punctures over the first 4 weeks of anti-tuberculous drugs were performed. Typical cell count and 
biochemical findings with lymphocyte predominance, low glucose and high protein on initial CSF were 
described. In 9% of cases, an atypical picture of polymorph predominance raised to 2000 x 106/L similar to 
a bacterial meningitis was described. Fluctuations in cell count and biochemistry were seen throughout the 
first month of anti-tuberculous therapy; cell count and protein fluctuated more than glucose. A paradoxical 
transient pleocytosis in the range of 500 x106/L with a polymorph predominance often occurred in the first 
two weeks of treatment. Protein levels were high initially; only 18% of children had values less than 0.8g/L. 
Sixty-one percent of the children showed decreasing protein trends overall, either uninterrupted or 
fluctuating. The remaining 39% had higher proteins at 4 weeks than on admission. Twenty seven percent 
of cases had initially negative or trace result for Pandy’s globulin test. By 4 weeks 39% had trace or no 
turbidity on performing Pandy’s test. The authors recommend that during early anti-tuberculous therapy, 
fluctuations in CSF as described on follow up CSF studies are common and should not be a reason to stop 
TB treatment. 
 
A later study at the same institution (70) reported on serial lumbar CSF changes in a randomized controlled 
study of adjunctive steroids in the treatment of paediatric TBM. One hundred and thirty one children with 
suspected or confirmed TBM again showed fluctuations over time in CSF protein, glucose and cell counts. 
Cell counts transiently worsened during the first month of combined TBM and steroid treatment, and then 
steadily decreased. Glucose rose steadily to reach normal levels only after the third week in the steroid 
treated arm. Protein and globulin levels remained high in the first month, gradually decreasing during the 
initial 4 weeks of combined TBM plus steroid treatment.  CSF lactate and adenylate kinase were also 
monitored but did not show a significant difference in rates of normalizing in the group treated with 
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adjuvant steroids. Schoeman et al.  (70) suggest that high CSF adenylate kinase may be associated with a 
poorer neurological outcome. CSF chloride was not reported on.  
 
A Kosovan study on a largely BCG unimmunized (81%) paediatric population with TBM examined serial 
lumbar punctures up to the third month on TBM treatment to explore the duration and nature of cyto-
biochemical changes in children treated for TBM (71). The authors found persistent CSF pleocytosis (50 – 
500 x106/L) for a mean of 70 days (range 56 to 92 days) on TBM treatment. Lymphocyte predominance 
ranged from a mean of 67% in the first CSF sample to 98% in the fourth CSF sample taken 3 months after 
TBM treatment. They described a positive Pandy reaction for CSF globulin in 96% of cases on initial LP, 
which remained positive in 65% of cases after repeat LP after 3 months on TB treatment. Protein levels 
were normal or raised (mean 1.86 g/L) on the initial CSF sample but remained high in the three subsequent 
CSF samples. Glucose levels were lower than normal in CSF samples throughout TBM treatment across 
the 3-month period. These levels ranged from a mean of 1.49 mmol/L on the first CSF sample to low/ 
normal (mean 2.10 mmol/L) after 3 months. The CSF: Blood glucose ratio was depressed. Chloride was 
not reported on. 
 
1.11 Knowledge gap 
A knowledge gap exists from the lack of data on differences in CSF parameters between ventricular and 
lumbar CSF in TBM (81), and on how ventricular CSF parameters and the differential between ventricular 
and lumbar CSF change over time. Ventricular CSF has not been as systematically studied as lumbar CSF 
in TBM. These are important issues because decisions about surgery may be influenced by CSF 
characteristics, and if the results between ventricular and lumbar CSF are different, the source of the sample 
is important in those decisions. Furthermore, many studies in TBM are based primarily on lumbar CSF, the 
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characteristics of which might not only reflect production from the CNS. In fact, the characteristics of 
lumbar CSF may be influenced by flow dynamics and a contribution from systemic sources to a greater 
degree than ventricular CSF (78,79). Therefore, whether lumbar CSF adequately reflects ventricular CSF, 
or analytes of intrathecal origin, can be questioned. 
 
1.12 Justification and significance of research  
Knowing that spinal factors may influence lumbar CSF characteristics, and that asymptomatic spinal 
disease is common in TBM, better characterisation of the differences and similarities between ventricular 
and lumbar CSF may be helpful. This may also help clarify how well ventricular CSF parameters can be 
predicted from lumbar CSF results and what implications this has for decisions about VPS insertion. Where 
there is only a ventricular sample (for example when an emergent external ventricular drain is in place), a 
better understanding of the ventricular findings on admission may help avoid a missed diagnosis.  
 
1.13 Aim and objectives 
This study aimed to examine ventricular and lumbar CSF parameters in children with probable and definite 
TBM, on admission and over 3 weeks of treatment.  
 
The primary objective was to describe the temporal profile of CSF cells, biochemistry, and microbiology 
in the lumbar and ventricular CSF compartments in TBM.  
 
The secondary objectives were to: 1) identify possible predictors of the differential; and 2) determine 
association between that differential and patient outcome. 
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CHAPTER 2: METHODOLOGY 
2.1 Study design 
A descriptive retrospective cohort study was conducted on data collected as part of two ongoing TBM 
studies (Ethics numbers HREC 318/2010 and 200/2014), which provided a convenience sample from which 
data were derived for use to inform future projects. Patient data collection was conducted from October 
2010 to March 2015.  
 
2.2 Selection of patients 
We screened all children treated at RCWMCH from October 2010 to March 2015 for suspected TBM and 
hydrocephalus and included those who had lumbar and/ or ventricular CSF sent for TB investigations and 
who met the research case definition of definite or probable TBM (4) (Appendix 2). Lumbar and ventricular 
CSF samples from day 1 to day 21 were included. Time-linked (paired) lumbar and ventricular CSF samples 
were taken for those patients who had received a lumbar puncture as well as neurosurgical interventions 
(ventricular CSF sampling) to treat raised ICP and hydrocephalus. These were typically taken in the 
operating room when an external ventricular drain (EVD) was placed as an emergency procedure and an 
air encephalogram and/or column test was done at the same time, or when a planned post-EVD air 
encephalogram/ column test were done in patients with EVDs in situ. Air encephalography and column 
tests have been previously described (33). Briefly, a lumbar air encephalogram involves the instillation of 
a small amount of air into the lumbar CSF space, sitting the patient upright thereafter, and performing a 
skull radiograph to determine if air is seen in the ventricular system, which indicates an open 
communicating CSF system. A column test is done only in patients with an EVD in situ; the patient is 
positioned for a lumbar puncture; a manometer is placed on the lumbar needle to check the opening 
pressure; this is compared to the opening pressure on a manometer attached to the ventricular drain (and 
zeroed at the same level) and then the cranial pressures are monitored as CSF is drained from the lumbar 
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needle. If the OP’s are equal and the pressures decrease to the same degree after CSF drainage a diagnosis 
of communicating hydrocephalus in made. Occasionally, a lumbar puncture was performed for therapeutic 
purposes, and an EVD or VPS was placed soon thereafter. These were also included as paired samples if 
the samples were taken within 24 hours of each other. However, samples were excluded if the lumbar 
puncture followed a procedure: CSF samples within 48 hours after neurosurgical procedures or air 
encephalograms were excluded to avoid the potential artefact (inflammatory response) of the intracranial 
procedure or intracranial air on subsequent CSF findings. Patients were excluded if there was an infection 
of the EVD or shunt.  
 
2.3 Data collection and sources 
Demographic and clinical data were collected from patient clinical notes. Lumbar and ventricular CSF 
laboratory data including glucose, protein, chloride, cell count and microbiological/ Mtb diagnostics on 
admission and during the first 21 days of hospitalisation were collected from the National Health Laboratory 
Service (NHLS) database. Radiological data from admission and follow up CT and MRI scans were 
reviewed by three senior pediatric radiologists and a senior pediatric neurosurgeon according to criteria 
previously published by the reviewers  (16), due to the paucity of standardised criteria. Reviewers were 
blinded to patient clinical characteristics and outcome. Disagreements were resolved through consultation 
and discussion until a consensus agreement was achieved. Specific features recorded included severity of 
hydrocephalus (mild, moderate, severe), presence of basal meningeal enhancement, presence of infarcts, 
presence of tuberculomas, presence and severity of spinal pathology (mild, moderate and severe), and CXR 
findings. Details of how these variables were recorded are included in Appendix 5. 
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Data were directly entered into an electronic Excel data collection spreadsheet on a secure password 
protected laptop. Patient identifiers were removed and re-coded to protect patient anonymity and privacy. 
Access to the anonymous dataset was restricted to the study investigators (MMed supervisors) and a UCT 
statistician as needed for data analysis purposes. 
 
2.4 Data analysis 
Data were exported from the electronic data collection instrument into the statistics package and coded. 
Before being analysed, the data was cleaned and verified. The data cleaning and verification process 
involved screening/ verifying missing data, and verifying if outlier CSF results were true values by 
reviewing patient clinical notes, scans and CSF patterns. STATA software version 14.1, R software version 
3.3.2, and SPSS version 25 (IBM) were used to analyse the data.  
 
2.5 Statistical analyses 
2.5.1 Clinical descriptive statistics 
Patient categorical baseline characteristics were described using number and percentage. Continuous 
variables were described using median, interquartile range (IQR), maximum to minimum or mean and 
standard deviations depending on data distribution. Variables studied were demographic, clinical and 
radiological features and CSF data obtained from both lumbar and ventricular compartments. Key cell count 
(polymorphonuclear cells, lymphocytes, total white cells) and biochemical (glucose, protein, chloride) 
parameters were analysed in the lumbar and ventricular CSF compartments. A p-value of <0.05 was 
considered significant.  
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To compare the difference between lumbar and ventricular CSF we first examined data for each 
compartment across all patients and all time points. Next, we identified patients who had paired samples of 
lumbar and ventricular CSF (taken within 24 hours of each other), and further analysed the difference 
between the compartments for these paired samples. Analysis of distribution of data demonstrated that data 
was not normally distributed therefore all statistical tests used were non-parametric tests. 
 
2.5.2 Comparisons between lumbar and ventricular CSF compartments overall (pooled)  
Temporal profiles of lumbar and ventricular CSF were analysed across time epochs of 4 days as not all 
patients had samples taken each day. This time frame would allow for adequate resolution to identify short 
term changes in CSF parameters.  
 
2.5.3. Comparison between CSF compartments for paired samples  
Using the paired, time-linked samples we conducted a Wilcoxon signed rank test to establish whether CSF 
chemistry (glucose, protein, chloride) and cell counts (polymorphonuclear cells, lymphocytes and WCC) 
were significantly different between the 2 compartments. Thereafter, the differential between paired lumbar 
and ventricular CSF parameters was calculated as lumbar minus ventricular CSF values for each parameter. 
Differenial was used as an index of the degree of difference between compartments. Next, a ratio of lumbar 
to ventricular samples was also calculated. Ratio was used to account for variation in absolute values. Data 
on the differentials and ratios are presented for each patient in whom paired samples were collected.  
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2.5.4 Analysis of lumbar or ventricular CSF analytes with radiology characteristics  
To examine the impact of the nature of hydrocephalus (communicating, non-communicating and uncertain), 
the presence of infarcts, tuberculomas and spinal disease, and the severity of spinal disease (mild, moderate-
severe) may have on perturbations of CSF parameters we analyzed the association between these radiology 
characteristics (in patients who had full brain and spine MRIs) and 1) the lowest glucose and chloride, and 
the highest protein and cell count in lumbar and ventricular CSF, 2) the ratios of lumbar and ventricular 
CSF chemistry and cytology, and 3) the differentials in lumbar and ventricular CSF chemistry and cytology. 
This included 108 analyses. 
 
According to published and clinically used thresholds for CSF composition at our institution, low glucose 
and chloride were defined as less than 2.2 mmol/L and 116 mmol/L respectively, high lymphocyte count 
as more than 5 x106/L, high polymorphonuclear count as any cells found x106/L, and high total white cell 
count as more than 10 x106/L (82,83).  Based on different thresholds used for elevated protein, we 
categorized protein as increased according to 1) the general CSF threshold of more than 0.4g/L (83), and 
2) the threshold of 0.8 g/L that has been found to have high specificity in the diagnosis of TBM  (3,32,82). 
Analyses were conducted using Mann-Whitney’s U or Kruskall Wallis tests, significance was set at 0.05, 
and significant results are accompanied by Box and Whisker Plots. 
 
2.5.5 Analysis of associations between patient outcomes and CSF compartment  
Patient outcome was assessed using the Pediatric Cerebral Performance Category Scale (84) (briefly, this 
is a 6 point scale comprising 1, normal; 2, mild disability; 3, moderate disability; 4, severe disability; 5, 
deep coma or vegetative state; 6, death) – Appendix 6. The PCPCS score was dichotomized for favorable 
outcome in survivors (PCPCS 1-3) and unfavorable outcome in survivors (PCPCS 4-5). Mortality at 12 
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months after admission was also recorded. The association between morbidity and mortality with CSF 
differentials and ratios was examined using Mann Whitney's U. Repeated measures were excluded (n=4 
samples). 
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CHAPTER 3: RESULTS 
 
A total of 81 children were enrolled in the study selected from all children treated for suspected TBM and 
hydrocephalus attending RCWMCH from October 2010 to March 2015. A flow diagram outlining patient 
selection is shown in Figure 1. 
Figure 1: Flowchart of Patient Selection Process 
  
The figure outlines the steps taken in selecting study patients. Exclusions were made based on evaluation of 
clinical, radiological and laboratory data. 
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3.1 Descriptive data of patient admission clinical characteristics 
 
Clinical features were reported based on availability of data recorded in the clinical records. Table 1 outlines 
patient demographic admission characteristics. The median age was 36 (2 – 156) months. Forty-nine 
children (61%) were male. Fifty seven percent (n=41) of the children were underweight for age. Most 
patients (n=74, 92%) were HIV negative, few were positive (n=6, 7%) and in one patient HIV status was 
unknown. Three (50%) of HIV co-infected patients were on anti-retroviral therapy.  
 
Table 1: Demographic Characteristics of Children with TBM and Hydrocephalus on Admission 
 
Patient parameter  
Age  36 (2-156) months 
Male 49 (60.5) 
Nutritional Status a (n=72)  
Normal weight ≥ -1 SD 31 (43) 
Underweight < -1 SD 41 (56.9) 
HIV positive b (n=80) 6 (7.5) 
TB Contactc (Total n=74) 30 (40.5) 
Demographic variables are presented as median (minimum – maximum), or number (percent). a not recorded in n=9 
(11%), b investigated in n=80, c recorded in n=74 (91%).  
 
Most children had constitutional symptoms (n=69, 88%) – Table 2. Fever was reported in 51 children 
(63%), weight loss in 44 (54%), and night sweats in 8 (10%). Most (n=58, 72%) had no cough. Mantoux 
tuberculin skin tests were positive in 40 (82%) of those tested.  
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Table 2: General Clinical Features of TB on Admission 
Patient parameter n (%) 
Constitutional symptoms a 
(Total n=78) 
69 (88.5) 
Fever  51 (63) 
Weight loss  44 (54.3) 
Night sweats  8 (9.9) 
Cough  23 (28.4) 
Positive Mantoux Result b   40 (81.6) 
Evidence of TB at other sites 29 (35.8) 
This table illustrates the clinical features related to TB infection in number (percentage). a Only recorded in n=78 
(96%), b Mantoux tests were only conducted in n=49 (61%) of patients due to a nationwide shortage of tests. 
 
Revised MRC TBM staging on initial presentation showed 37% of patients in stage 3 (n=30), 3.6% (n=28) 
in stage 2b, and 21% (n=17) in stage 2a. Only 6 (7%) children had no neurological deficits. The mortality 
rate was 13.6%. Definite TBM was diagnosed in 35 (43.2%) of patients, and probable TBM in 46 (56.8%) 
patients.  
 
Table 3 shows the nature of hydrocephalus in the cohort. Fifty-eight patients (71.6%) had communicating 
hydrocephalus; 13 (16%) had non-communicating hydrocephalus; 10 (12.3%) had uncertain results due to 
a failed study (lumbar puncture needle was in the subarachnoid space but no CSF could be collected and/or 
air was not visible on the skull radiograph). Two patients had an EVD placed emergently because of their 
poor clinical condition, but died before an air encephalogram or column test could be performed.  
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Table 3: Classification of Children with TB Meningitis and Hydrocephalus 
Patient parameter n (%); n=81 
Revised MRC TBM Stage  
Stage 1 6 (7.4) 
Stage 2a 17 (21) 
Stage 2b 28 (34.6) 
Stage 3 30 (37) 
TB Meningitis (TBM) Diagnosis  
Definite TBM 35 (43.2) 
Probable TBM 46 (56.8) 
Nature of Hydrocephalus (Air Encephalogram and/or column 
test)  
 
Communicating  58 (71.6) 
Non-communicating 13 (16) 
Uncertain (Failed study/ study not performed)  10 (12.3) 
Results are illustrated as number (percentage). Results for 81 study patients are reported. Revised MRC TBM Stage 
is a system of staging severity of TBM based on level of consciousness and neurological fallout (van Toorn et al. , 
2012). 
 
Table 4 displays the neurological condition of the cohort. Percentages are given either for the full cohort, 
where the data were collected for all patients, or for the number of patients in whom that information was 
documented. The median admission GCS score was 11 (range 5-15). Most patients (n=72, 88.9%) presented 
with reduced consciousness. Focal neurological signs were documented in 58 (71.6%) patients (including 
cranial nerve palsies and hemiparesis). Only 58 patients had their lumbar opening pressure recorded, 38 
(66%) of whom had raised intracranial pressure (defined according to RCWMCH Neurosurgery 
Department Clinical Protocols as opening pressure >27cmH2O/ 20mmHg). Papilledema was present in 15 
(40.5%) of the 37 patients in whom fundoscopy was done. Cushing’s reflex is a physiological response to 
raised intracranial pressure resulting in high blood pressure and low heart rate, detectable on clinical 
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examination. Thirty-two (57.1%) of the 56 patients whose blood pressure was documented on admission 
had high blood pressure. Twenty-seven (45.8%) of the 59 patients whose heart rate was documented on 
admission had a low heart rate for age. Headache was recorded in 26 (61.9%) children over 5 years old 
(n=42). Irritability was reported in 34 (41.8%) patients, vomiting in 42 (51.9%), neck stiffness in 58 
(71.6%), and seizures were documented in 32 children (39.5%). A bulging fontanelle was found in 11 
children with an open fontanelle (52.4%). 
Table 4: Neurological Features of Children with TB Meningitis and Hydrocephalus 
Patient parameter n (%) 
Focal neurological signs 58 (71.6) 
Raised Intracranial Pressure a  38 (65.5) 
Raised Blood Pressure for age b  32 (57.1) 
Bradycardia c 27 (45.8) 
Headache d 26 (61.9) 
Irritability 34 (41.8) 
Vomiting 42 (51.9) 
Neck stiffness 58 (71.6) 
Seizures 32 (39.5) 
Abnormal posturing 15 (18.5) 
Altered level of consciousness (GCS<15) 72 (88.9) 
Lethargy 72 (88.9) 
Not walking e  12 (21.4) 
Bulging anterior fontanelle f  11 (52.4) 
Papilledema g 15 (40.5) 
Sun setting sign  3 (3.7) 
Data are presented as absolute numbers (percentages) for signs and symptoms. Raised blood pressure was determined 
using standard pediatric vital parameter tables and is reported from recordings within the first 48 hours of admission. 
a Raised ICP was defined as an opening CSF pressure of > 27cmH2O measured using a manometer, the opening 
pressure was reported in 58 patients, b Blood pressure for age was reported in 56 patients, c Low heart rate for age was 
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reported in 59 patients,  d Headache was only applicable to children > 5years old (n=42). e This was determined in 
children ≥ 18 months who had previously been walking (n=56). f Applicable to children ≤ 18 months, n=21). g 
Fundoscopy was only performed in 37 patients.  
 
 
3.1.2 CNS imaging in TBM with hydrocephalus 
Findings from all scans, admission and follow-up, are presented in Table 5. All patients included in the 
study had hydrocephalus. Severity of hydrocephalus and basal enhancement was graded using criteria 
previously defined by our institution (16) (Appendix 5). Twenty-two patients (27.2%) had mild 
hydrocephalus, 32 (38.8%) moderate, and 27 (33.8%) severe. Seventy-six patients (97.4%) demonstrated 
basal meningeal enhancement on admission in keeping with TBM, graded as mild in 33 (47.1%) patients, 
moderate in 32 (45.7%), and severe in 5 (7.1%). Fifty-one (63%) patients had brain infarcts; most of these 
had multiple infarcts (n=31, 60.8% of all infarcts). Thirty-seven patients (47.4%) had tuberculomas. Spinal 
imaging does not form part of standard imaging protocol at our institution; only thirty-nine patients (48.2%) 
had spinal scans that were done as part of a prospective study. Thirty-one of these scans (79.5%) were 
abnormal: most (n=30, 76,9%) showed features of spinal arachnoiditis, three (7.7%) had a single spinal 
tuberculoma and another three (7.7%) multiple spinal tuberculomas. Spinal disease severity was defined by 
institutional criteria (Appendix 5). Seventeen patients (54.8%) had mild, 8 (25.8%) moderate and 6 (19.4%) 
severe spinal disease. Severe spinal disease was characterised by extensive involvement of the spinal cord 
and subarachnoid space. 
 
Of the 81 children enrolled in this study, 73 (90.1%) had lumbar CSF and 55 (67.9%) had ventricular 
samples. Twenty-nine patients (35.8%) had paired lumbar – ventricular samples taken at the same time or 
within 24 hours of each other; 4 patients (13.8%) had 2 CSF pairs.  
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Table 5:   CT and MRI Brain and Spine Features of TBM with Hydrocephalus 
Scan Feature n (%) 
Hydrocephalusa 81 (100) 
 Non-communicating 13 (16) 
 Communicating 58 (71.6) 
 Uncertain 9 (11.1) 
Admission enhancement presentb 76 (97.4) 
Infarcts present 51 (63) 
Tuberculoma presentb 37 (47.4) 
Spinal disease presentc 31 (79.5) 
Spinal disease severity  
 Mild 17 (54.8) 
 Moderate 8 (25.8) 
 Severe 6 (19.4) 
Data are presented as number (percentage). a One patient was shunted immediately and did not have an air 
encephalogram or column test. b Three patients did not receive contrast on admission scan. c Spinal imaging was 
performed in 39 patients.  
 
Figure 2 shows a breakdown of the 35 patients (43.2%) whose CSF yielded a positive result from one of 
the 3 TB microbiological tests performed. Relative to the entire cohort, 29 (36%) had positive TB culture, 
12 (15%) had positive AFB, 34 (42%) had positive Gene Xpert. No patient (0%) had combined culture 
positivity plus AFB. Twenty-two (27%) patients had combined positive results for TB culture and Gene 
Xpert. Four (5%) were both AFB and Gene Xpert positive. The CSF TB microbiology results reported are 
disaggregated according to lumbar or ventricular CSF compartment. 
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Figure 2: TBM Confirmed on CSF Microbiology 
 
 
 
 
The graph illustrates positive CSF microbiology: TB culture (gold standard), AFB (Acid Fast Bacilli) and DNA Gene 
Xpert. Relative to the total cohort of 81 patients, 35 patients had a positive TB CSF microbiology result. The data 
table shows percentages and absolute numbers for lumbar and ventricular CSF analytes. Yellow bars represent 
ventricular CSF percentage. Grey bars represent ventricular CSF absolute number. Orange bars represent lumbar CSF 
percentage, Blue bars represent lumbar CSF absolute number. 
 
 
3.2 CSF temporal profiles in lumbar versus ventricular CSF compartments (pooled samples) 
The following tables 6 - 7 and figures 3 - 8 indicate overall temporal profiles of lumbar CSF and ventricular 
CSF parameters measured over the first 3 weeks post-admission. All data points for each CSF compartment 
were analyzed.  
0 5 10 15 20 25 30 35
Culture
AFB
Xpert
Culture+ AFB
Culture+ Xpert
AFB+ Xpert
Culture+ AFB+ Xpert
Any TB positive
Culture AFB Xpert Culture+AFB
Culture+
Xpert AFB+ Xpert
Culture+
AFB+ Xpert
Any TB
positive
Ventricular % 16 5 16 0 12 1 2 21
Ventricular n 13 4 13 0 10 1 2 17
Lumbar % 26 10 31 0 18 4 6 30
Lumbar n 21 8 25 0 15 3 5 24
Positive CSF TB Microbiology Result
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3.2.1 Lumbar CSF results 
Over the first 21 days post-admission lumbar CSF glucose had a median of 2.2 mmol/L (IQR 1.5-2.9 
mmol/L), protein values had a median of 2 g/L (IQR 1.2-2.3 g/L), and chloride had a median of 112 g/L 
(IQR 107-119 g/L). Lumbar CSF polymorphonuclear cells had a median of 15 x106/L (IQR 4-50 x106/L), 
lymphocytes had a median of 135 x106/L (IQR 63-286 x106/L), and total white cells had a median of 165 
x106/L (IQR 86-340 x106/L).  Lumbar CSF median glucose and chloride fell below the normal limits. CSF 
protein was above the normal value of 0.4 g/L in almost all (n=195, 97.5%) lumbar samples, and above 0.8 
g/L in 87% (n=174) throughout the first 3 weeks of hospitalization. Cell counts were always above normal. 
The lumbar CSF analytes over 4-day time epochs are shown below (Table 6) and trends described under 
their corresponding graphs.  
3.2.2 Ventricular CSF results 
Values are shown in Table 7. Over the first 21 days post-admission, the medians and IQR for ventricular 
CSF biochemistry were: glucose 3 mmol/L (IQR 2.6–3.6 mmol/L), protein 0.5 g/L (IQR 0.3-0.9 g/L), and 
chloride 114.5 g/L (IQR 109-120 g/L). For cells, medians and IQR were: polymorphonuclear cells 2 x106/L 
(IQR 0-5.5 x106/L), lymphocytes 21 x106/L (IQR 9-40 x106/L), and total white cells 22 x106/L (IQR 10-45 
x106/L). Ventricular CSF median glucose fell within normal limits, chloride was below normal, and protein 
was > 0.4 g/L in n=58 (65.2%), and > 0.8 g/L in n=28 (31.5%) of samples. 
 
Table 6: Description of Lumbar CSF Biochemistry and Cell Count Over Time 
Time Epochs Days 1-4 5-8 9-12 13-16 17-21 Overall 
Glucose (mmol/L) Median 1.6 2.6 2.3 2.4 2.8 2.2 
 Minimum 0.3 1.1 1.2 0.8 1.2 0.3 
 Maximum 4.8 4.5 3.9 4.3 4.4 4.8 
 25th % (Q1) 1.1 2.1 1.8 1.7 2.4 1.5 
 75th% (Q2) 2.3 3.1 3.1 3.0 3.2 2.9 
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Chloride (mmol/L) Median 109 114.5 114 114.5 119 112 
 Minimum 93 95 100 100 101 93 
 Maximum 147 130 128 140 172 172 
 25th % (Q1) 105 107 110 111.3 113.5 107 
 75th% (Q2) 113 121.8 120 123 127 119 
Protein (g/L) Median 2 2 1.7 1.5 1.3 2 
 Minimum 0.3 0.7 0.4 0.3 0.2 0.2 
 Maximum 48.9 35.4 14.7 9.7 6.1 48.9 
 25th % (Q1) 1.4 1.3 0.9 0.7 0.9 1.2 
 75th% (Q2) 2.8 2.5 2.1 2.1 2.2 2.3 
Polymorphonuclear 
cells (x106/L) 
Median 18 17 7 11 8 15 
 Minimum 0 0 0 0 0 0 
 Maximum 635 270 121 184 405 635 
 25th % (Q1) 6 3 1 4 2 4 
 75th% (Q2) 57 55 35 50 31 50 
Lymphocytes  
(x106/L) 
Median 137 268 138 100 68 135 
 Minimum 8 21 11 0 20 0 
 Maximum 621 2275 870 1855 270 2275 
 25th % (Q1) 56 118 56 64.5 40 63 
 75th% (Q2) 286 455 199 329 112.5 286 
TWCC (x106/L) Median 170 305 176 116 73 165 
 Minimum 9 23 11 5 23 5 
 Maximum 995 2280 920 1960 575 2280 
 25th % (Q1) 86 132 90 68 59 86 
 75th% (Q2) 330 615 242 455.5 144.5 340 
This table depicts descriptive statistics for lumbar CSF compartment analytes in time epochs (4 days) and overall 
values across the 21 days post admission. The overall values are the values calculated for the full dataset (all time 
points). Biochemistry analytes were glucose, protein and chloride. Cellular analytes were polymorphonuclear cells , 
lymphocytes and total white cell count (TWCC). 
 
Table 7: Description of Ventricular CSF Biochemistry and Cell Count Over Time 
Time Epochs Days 1-4 5-8 9-12 13-16 17-21 Overall 
Glucose (mmol/L) Median 3.1 3.5 3 3.5 2.5 3 
 Minimum 1.2 1.4 2.3 2.8 2.1 1.2 
 Maximum 5.4 5.2 4.4 3.9 3.2 5.4 
 25th % (Q1) 2.6 2.6 2.4 2.6 2.1 2.6 
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 75th% (Q2) 3.6 3.7 3.3 3.9 3.2 3.6 
Chloride (mmol/L) Median 112 116 116 117.5 118 114.5 
 Minimum 89 93 106 114 115 89 
 Maximum 148 149 133 121 118 149 
 25th % (Q1) 108 110 112 114.3 115 109 
 75th% (Q2) 119 121 121.5 120.8 118 120 
Protein (g/L) Median 0.5 0.8 0.4 0.8 1.4 0.5 
 Minimum 0.1 0.1 0.2 0.2 0.9 0.1 
 Maximum 2 2.7 2 1 2 2.7 
 25th % (Q1) 0.3 0.2 0.3 0.4 0.9 0.3 
 75th% (Q2) 0.8 1.2 1.3 1 2.1 0.9 
Polymorphonuclear 
cells (x106/L) 
Median 3 2 2 5.5 3 2 
 Minimum 0 0 0 1 0 0 
 Maximum 74 15 13 13 10 74 
 25th % (Q1) 0 0.3 0 2 0 0 
 75th% (Q2) 5 5.5 5 11.3 10 5.5 
Lymphocytes  
(x106/L) 
Median 13 25.5 22 36 98 21 
 Minimum 0 4 5 17 93 0 
 Maximum 100 480 84 57 136 480 
 25th % (Q1) 6 12.3 9 19.8 93 9 
 75th% (Q2) 35 36.5 67 53.8 136 40 
TWCC (x106/L) Median 15 29 23 41.5 103 22 
 Minimum 0 0 5 18 101 0 
 Maximum 139 495 89 70 136 495 
 25th % (Q1) 9 11.5 11 22 101 10 
 75th% (Q2) 39 40.5 73 64.8 136 45 
This table depicts descriptive statistics for ventricular CSF compartment analytes over 21 days post admission. 
Biochemistry analytes were glucose, protein and chloride. Cells were polymorphonuclear cells, lymphocytes  and total 
white cell count (TWCC). 
 
3.3 Temporal profiles of lumbar and ventricular CSF samples 
Time point 17-21 days was excluded from the plots because the numbers were too few. Profiles including 
this time point are shown in Appendix 9. 
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3.3.1 CSF glucose temporal profile 
Lumbar CSF glucose began low and normalised by the start of week 2 (Figure 3). Ventricular CSF glucose 
remained within the normal range throughout the 21-day period. Ventricular CSF glucose concentrations 
were greater than in lumbar CSF. 
 
Figure 3:  
 
Temporal changes in overall lumbar and ventricular CSF glucose over time epochs of 4 days for the first 16 days after 
admission in children with TBM and hydrocephalus. The horizontal dotted line represents the minimum normal 
glucose value of 2.2 mmol/L. Median lumbar CSF values are shown as a green line. Median ventricular CSF values 
are shown as a blue line. Number of samples per time point with lumbar CSF in green and ventricular CSF in blue: 
Day 1-4 (n=89, 59), Day 5-8 (n=39, 14), Day 9-12 (n=31, 10), Day 13-16 (n=20, 4) 
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3.3.2 CSF chloride temporal profile 
Chloride concentrations in both lumbar and ventricular CSF began low, but increased by the end of the first 
week. Ventricular CSF chloride concentrations were greater than those in lumbar CSF (Figure 4). 
 
 
Figure 4:  
 
 
Temporal changes in lumbar and ventricular CSF chloride over time epochs of 4 days for the first 16 days after 
admission in children with TBM and hydrocephalus. The horizontal dotted line represents the minimum normal 
chloride value of 116 mmol/L. Median lumbar CSF values are shown as a green line. Median ventricular CSF values 
are shown as a blue line. Number of samples per time point with lumbar CSF in green and ventricular CSF in blue: 
Day 1-4 (n=85, 59), Day 5-8 (n=36, 14), Day 9-12 (n=31, 9), Day 13-16 (n=20, 4). 
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3.3.3 CSF protein temporal profile 
Lumbar CSF protein was greater than ventricular CSF protein. Lumbar CSF protein remained above the 
limits of 0.4 and 0.8 g/L throughout the first 3 weeks of hospitalization. Median ventricular CSF protein 
was above the limit of 0.4 g/L (Figure 5) but not the limit of 0.8 g/L (Figure 5). 
 
Figure 5:  
 
Temporal changes in lumbar and ventricular CSF protein over specific time epochs of 4 days for the first 16 days after 
admission in children with TBM and hydrocephalus. The horizontal dotted line represents the maximum protein value 
of 0.4 g/L and the horizontal solid line represents 0.8 g/L respectively. Median lumbar CSF values are shown as a 
green line. Median ventricular CSF values are shown as a blue line. Number of samples per time point with lumbar 
CSF in green and ventricular CSF in blue: Day 1-4 (n=89, 58), Day 5-8 (n=38, 14), Day 9-12 (n=30, 10), Day 13-16 
(n=18, 4). 
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3.3.4 CSF polymorphonuclear cells temporal profile 
Lumbar and ventricular CSF polymorphonuclear cell counts remained above zero for the 3 weeks of 
hospitalisation. Lumbar CSF counts were higher than ventricular counts, Figure 6.  
Figure 6:  
 
 
 
Temporal changes in lumbar and ventricular CSF polymorphonuclear cells over specific time epochs of 4 days for the 
first 16 days after admission in children with TBM and hydrocephalus. The horizontal dotted line represents the 
maximum normal polymorphonuclear cell value of 0 x106/L. Median lumbar CSF values are shown as a green line. 
Median ventricular CSF values are shown as a blue line. Number of samples per time point with lumbar CSF in green 
and ventricular CSF in blue: Day 1-4 (n=91, 59), Day 5-8 (n=39, 16), Day 9-12 (n=31, 11), Day 13-16 (n=21, 4). 
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3.3.5 CSF lymphocytes temporal profile 
Lumbar CSF lymphocytes were elevated overall; they peaked at day 5-8. Ventricular CSF lymphocytes 
counts were raised, but remained lower than lumbar CSF counts, Figure 7.  
 
Figure 7:  
 
 
The graph shows changes in lumbar and ventricular CSF lymphocytes over specific time epochs of 4 days for the first 
16 days after admission in children with TBM and hydrocephalus. The horizontal dotted line represents the maximum 
normal lymphocyte value of 5 x106/L. Median lumbar CSF values are shown as a green line. Median ventricular CSF 
values are shown as a blue line. Number of samples per time point with lumbar CSF in green and ventricular CSF in 
blue: Day 1-4 (n=91, 59), Day 5-8 (n=39, 16), Day 9-12 (n=31, 11), Day 13-16 (n=21, 4). 
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3.3.6 CSF total white cell count temporal profile 
The total white cell count reflected the patterns seen for polymorphonuclear cells and lymphocytes. Lumbar 
and ventricular CSF values were elevated, lumbar values to a greater degree. Lumbar values peaked on 
days 5-8. 
 
Figure 8:  
 
 
The graph shows changes in unpaired lumbar and ventricular CSF total white cell count over specific time epochs of 
4 days for the first 16 days after admission in children with TBM and hydrocephalus. The horizontal dotted line 
represents the maximum normal total white cell count value of 10 x106/L. Total white cells are derived from the sum 
of polymorphonuclear cells and lymphocytes. Median lumbar CSF values are shown as a solid green line. Median 
ventricular CSF values are shown as a solid blue line. Number of samples per time point with lumbar CSF in green 
and ventricular CSF in blue: Day 1-4 (n=91, 59), Day 5-8 (n=39, 16), Day 9-12 (n=31, 11), Day 13-16 (n=21, 4). 
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3.4 Paired (time-linked) lumbar and ventricular CSF parameters 
3.4.1 Paired lumbar and ventricular CSF biochemistry 
A total of 33 paired lumbar and ventricular CSF samples were collected from 29 patients; most of whom 
only had 1 sample pair (n=25, 86%). Most (81.8%) pairs were collected in days 1 to 3 post-admission.  One 
patient did not have lumbar CSF tested for biochemistry parameters and was excluded from analysis of 
biochemistry values but included for cell count comparison. Summary statistics of paired lumbar and 
ventricular CSF biochemistry results are summarised in Table 8. Table 9 shows the individual values for 
each paired lumbar-ventricular CSF sample, and the differential and ratio between the concentrations.  
Glucose: Only 32 paired samples had glucose concentrations analysed. Most ventricular CSF glucose 
values (n= 30/32, 93.8%) fell within the normal range of 2.2 to 4.0 mmol/L, whereas most (n= 25/32, 
78.1%) lumbar glucose values were low. The vast majority (n=30/32, 93.8%) of the ventricular CSF glucose 
values were higher than lumbar glucose values. The differences between the compartments was significant 
(p<0.001). The median differential between the compartments (calculated as lumbar-ventricular) was -1.8 
(IQR  2.1 to 1.4). The median ratio (lumbar/ ventricular) was 0.4 (IQR 0.2 to 0.6). 
Protein: Only 31 paired samples had protein concentrations analysed. All lumbar protein values were > 0.8 
g/L (n=31/31, 100%), whereas only 19 (61.3%) ventricular protein values were > 0.4 g/L, and 7 (22.6%) 
were > 0.8 g/L. All lumbar CSF protein values were significantly greater than corresponding paired 
ventricular protein values (p<0.001). The median protein differential was 1.5 g/L (IQR 1.1 to 2.8). The 
median protein ratio was 4 (4.7 to 4.5).  
Chloride: Only 31 paired samples had chloride concentrations analysed. In most patient (n=24/31, 77.4%) 
lumbar chloride was below the normal limit; 71% (n=22/31) of ventricular values were abnormal. Most 
patients (n=23, 74.2%) had higher ventricular than lumbar values; the difference between the compartments 
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was statistically significant (p=0.01). The median chloride differential was -4 (IQR -3.5 to -4.5).  The 
median chloride ratio was 0.96 (IQR 0.97 to 0.96). 
 
Table 8: Summary Statistics for Lumbar and Ventricular Paired CSF Biochemistry Analytes  
 Glucose (mmol/L) Protein (g/L) Chloride (mmol/L) 
CSF Lumbar Ventricular Lumbar Ventricular Lumbar Ventricular 
MIN 0.3 1.2 0.9 0.2 95 93 
MAX 3 4.5 48.9 1.5 131 126 
MEDIAN 1.2 3 2 0.5 108 112 
p-value (of 
medians) *p<0.001 *p<0.001 *p=0.01 
25th (Q1) 0.7 2.8 1.4 0.3 104 107.5 
75th (Q3) 2.1 3.5 3.6 0.8 114 118.5 
Descriptive data for paired lumbar and ventricular CSF biochemistry analytes glucose (n=32), protein (n=31), chloride 
(n=31). P-values of medians between lumbar and ventricular compartments are indicated. ‘*’ denotes statistical 
significance. 
 
 
Table 9: Paired Lumbar and Ventricular CSF Biochemical Parameters 
Patient 
No 
CSF Biochemistry 
Glucose (mmol/L) 
(Normal 2.2-4.0) 
Protein (g/L) 
(Normal 0.2-0.8) 
Chloride (mmol/L) 
(Normal 116-130) 
Lumbar Vent Diff Ratio Lumbar Vent Diff Ratio Lumbar Vent Diff Ratio 
2 0.3 2.4 -2.1 0.1 1.1 0.7 0.4 1.6  109 110 -1 1 
4 0.5 3 -2.5 0.2 48.9 0.5 48.4 97.8  102 123 -21 0.8 
5 2.7 2.8 -0.1 1 11.8 0.5 11.3 23.6  97 94 3 1 
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6 0.6 2.8 -2.2 0.2 1 0.3 0.7 3.3  117 121 -4 1 
11 0.7 2.9 -2.2 0.2 7.8 0.8 7.1 9.8  113 126 -13 0.9 
11 1.2 2.8 -1.6 0.4 15.5 1.1 14.5 14.1  95 93 2 1 
12 1.3 3.4 -2.1 0.4 5.4 0.9 4.5 6   109  0 
16 3 3 0 1 1.4 0.8 0.7 1.8  104 107 -3 1 
19 1 4.3 -3.3 0.2 2 0.2 1.9 10 121 102 19 1.2 
20 1.2 3.2 -2 0.4 13.5 0.3 13.2 45  101 111 -10 0.9 
20 2.8 4.4 -1.6 0.6 35.4 0.2 35.2 177  104 120 -16 0.9 
22 2.1 3.5 -1.4 0.6 1.2 0.5 0.8 2.4 108 114 -6 1 
22 3 1.5 1.5 2 2.3 0.4 1.8 5.8  118 106 12 1.1 
23 0.7 1.2 -0.5 0.6 3.7 1.5 2.2 2.5 131 108 23 1.2 
25 2.1 3.7 -1.6 0.6 3.6 0.4 3.2 9  109 115 -6 1 
29 1.6 3.6 -2 0.4 2.4 0.3 2.1 8 104 103 1 1 
31 0.3 3.3 -3 0.1 1.4 0.2 1.2 7   104 109 -5 1 
35 0.8 3 -2.2 0.3 1.4 0.6 0.8 2.3 109 112 -3 1 
36 1.3 2.5 -1.2 0.5 1.6 0.4 1.2 4  105 110 -5 1 
41 0.7 3.7 -3 0.2 2 1.4 0.7 1.4 106 107 -1 1 
43 1.8 3.9 -2.1 0.5 3 1.3 1.7 2.3 107 113 -6 1 
48 2.9 3 -0.1 1 2 0.8 1.6 2.7 113 116 -3 1 
52 0.8 4.5 -3.7 0.2 2 0.4 1.6 5  111 119 -8 0.9 
53 1 2.8 -1.8 0.4 2 0.7 1.3 2.8  116 120 -4 1 
55 1.2 2.3 -1.1 0.5 2 0.4 1.6 5 106 112 -6 1 
57 1.2 3.5 -2.3 0.3 0.9 0.2 0.6 4.5  107 113 -6 1 
57 1.6 3.3 -1.7 0.5 2 0.3 1.7 6.7  111 113 -2 1 
58 2 3.5 -1.5 0.6 1.3 0.8 0.5 1.6 121 122 -1 1 
63 2.5 3 -0.5 0.8  1   106 121 -15 0.9 
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72 1.1 3 -1.9 0.4 1.3 0.5 0.8 2.6 114 112 2 1 
73 2.5 3.2 -0.7 0.8 1.1 0.9 0.1 1.2 119 118 1 1 
81 0.6 2.6 -2 0.2 2.3 0.8 1.5 2.9 107 109 -2 1 
The table shows 28 of the 29 patients with paired lumbar-ventricular CSF (n=32) biochemical analytes (glucose, 
protein, chloride), their differentials and ratios (%) – patient 1’s data are not shown as lumbar chemistry tests were 
not performed. Normal ranges according to standard National Health Laboratory Services parameters are shown in 
brackets. The abbreviations “Vent” = ventricular. “Diff” = Differential. Differentials were calculated as lumbar-
ventricular value. Ratios were calculated as lumbar/ ventricular value. Lumbar and ventricular paired samples were 
collected within 24hrs of each other. Blank space represents missing data when investigations were not performed. 
 
3.4.2 Paired lumbar and ventricular CSF cell counts 
Table 10 depicts summary statistics and Table 11 depicts individual absolute values for paired lumbar and 
ventricular CSF cell results in the 29 patients with CSF pairs. In general, values for all cells were higher in 
lumbar compared to ventricular samples, and these differences were statistically significant (p<0.001 for 
polymorphonuclear cells, lymphocytes, and total white cell count). In 5 patients (15.2%) the ventricular 
polymorphonuclear cell counts was higher than the lumbar CSF. Nine ventricular CSF samples (27.3%) 
and 4 (12.1%) lumbar CSF samples had normal polymorphonuclear cell counts of 0 x106/L. All lumbar 
CSF samples (n=33, 100%) had raised lymphocyte and total white cell counts. Four (12.1%) ventricular 
samples had lymphocyte counts of </= 5 x106/L and 8 (24.2%) had total white cell counts of </= 10 x106/L. 
The median polymorphonuclear cell differential (lumbar minus ventricular value) was 9 (IQR 3 to 47); 
lymphocyte differential was 128 (IQR 40 to 237), and for total white cell count this was 179 (IQR 63 to 
252) x106/L.  
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Table 10: Summary Statistics for Lumbar and Ventricular Paired CSF Cell Counts  
 
Polymorphonuclear cells 
(x106/L) 
Lymphocytes 
(x106/L) 
Total white cell count 
(x106/L) 
 Lumbar Ventricular Lumbar Ventricular Lumbar Ventricular 
MIN 0 0 10 0 21 0 
MAX 280 74 2275 136 2280 139 
MEDIAN 12 3 149 21 202 23 
p-value (of 
medians) *p<0.001 *p<0.001 *p<0.001 
25th (Q1) 3 0 48 8 74 11 
75th (Q3) 53 6 282 45 309 57 
This table shows descriptive statistical findings for paired lumbar and ventricular CSF cytology analytes 
polymorphonuclear cells (n=33), lymphocytes (n=33), total white cell count (n=33). Paired CSF were taken on 
admission and during subsequent weeks. P-values of medians for paired lumbar and ventricular compartments are 
indicated. ‘*’ denotes statistical significance. 
 
 
Table 11: Paired Lumbar and Ventricular CSF Cell Count Parameters 
Patient 
No 
CSF cell count 
Polymorphonuclear cells 
(x106/L) 
(normal = x106/L) 
Lymphocytes 
(x106/L) 
(normal </= 5x106/L) 
Total white cell count 
(x106/L) 
(normal </=10 x106/L) 
Lumbar Vent Diff Ratio Lumbar Vent Diff Ratio Lumbar Vent Diff Ratio 
1 11 3 8 3.7 205 24 181 8.5 216 27 189 8 
2 4 2 2 2 411 100 311 4.1 415 102 313 4.1 
4 15 1 14 15 360 8 352 45 375 9 366 41.7 
5 0 0 0 0 270 27 243 10 270 27 243 10 
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6 4 0 4 0 22 11 11 2 26 11 15 2.4 
11 280 0 280 0 40 6 34 6.7 320 6 314 53.3 
11 50 0 50 0 60 5 55 12 110 5 105 22 
12 1 2 -1 0.5 74 24 50 3.1 75 26 49 2.9 
16 74 5 69 14.8 71 8 63 8.9 145 13 132 11.2 
19 12 0 12 0 286 0 286 0 298 0 298 0 
20 0 0 0 0 443 10 433 44.3 443 10 433 44.3 
20 5 4 1 1.2 2275 38 2237 59.9 2280 42 2238 54.3 
22 63 20 43 3.2 139 45 94 3.1 202 65 137 3.1 
22 30 15 15 2 425 95 330 4.5 455 110 345 4.1 
23 12 74 -62 0.2 158 65 93 2.4 170 139 31 1.2 
25 150 3 147 50 115 9 106 12.8 265 12 253 22.1 
29 12 7 5 1.7 149 21 128 7.1 161 28 133 5.8 
31 59 10 49 5.9 10 1 9 10 69 11 58 6.3 
35 38 3 35 12.7 35 5 30 7 73 8 65 9.1 
36 19 3 16 6.3 22 17 5 1.3 41 20 21 2 
41 1 0 1 0 258 45 213 5.7 259 45 214 5.8 
43 58 5 53 11.6 277 51 226 5.4 335 56 279 6 
48 90 2 88 45 100 10 90 10 190 12 178 15.8 
52 8 1 7 8 176 37 139 4.8 184 38 146 4.8 
53 1 0 1 0 37 6 31 6.2 38 6 32 6.3 
55 0 2 -2 0 286 21 265 13.6 286 23 263 12.4 
57 6 3 3 2 15 6 9 2.5 21 9 12 2.3 
57 0 2 -2 0 55 9 46 6.1 55 11 44 5 
58 16 7 9 2.3 201 51 150 3.9 217 58 159 3.7 
63 55 13 42 4.2 1705 57 1648 29.9 1760 70 1690 25.1 
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72 3 27 -24 0.1 71 40 31 1.8 74 67 7 1.1 
73 2 0 2 0 202 136 66 1.5 204 136 68 1.5 
81 17 3 14 5.7 40 16 24 2.5 57 19 38 3 
Descriptive data for patients (n=29) with paired lumbar-ventricular CSF (n=33) cytology analytes (polymorphonuclear 
cells, lymphocytes and total white cell count), their differentials and ratios (presented as %). The abbreviations “Vent” 
= ventricular. “Diff” = Differential. Normal ranges according to standard RCWMCC NHLS Laboratory parameters 
are shown in brackets. Differentials were calculated as lumbar-ventricular value. Ratios were calculated as lumbar/ 
ventricular value. Lumbar and ventricular paired samples were collected within 24hrs of each other. Blank space 
represents missing data when investigations were not performed. 
 
 
3.5 Analysis of unpaired lumbar and ventricular CSF biochemistry and cell count against radiology 
characteristics 
3.5.1 Minimum and Maximum lumbar and ventricular CSF chemistry and cell counts 
In unpaired, non time-linked CSF samples, only maximum lumbar CSF protein demonstrated a significant 
association with spinal disease severity (p=0.04), with higher protein concentrations observed in patients 
with moderate-severe spinal disease (Figure 9). There were no significant associations found between 
ventricular CSF and radiology characteristics.  
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Figure 9: Box and Whisker Plot for Highest Lumbar CSF Protein Based on Spinal Disease Severity 
 
 
 
The box plot demonstrates the maximum lumbar CSF protein reported across the study cohort. Protein for 200 lumbar 
CSF samples were analysed. Mild spinal disease (n=17) was defined as a thin layer of exudate surrounding spinal cord 
and nerve roots, moderate as the presence of plaques or clumping of spinal nerve roots, and severe as the presence of 
extensive exudate in surrounding spinal cord and nerve roots or in subarachnoid space (moderate-severe spinal disease 
n=14).  
 
3.5.2 Lumbar and ventricular CSF chemistry and cell count differentials 
There were no other significant relationships with CSF differentials and radiology characteristics. 
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3.5.3 Lumbar and ventricular CSF chemistry and cell count ratios 
The ratio of CSF glucose between the lumbar and ventricular compartments was significantly greater in 
patients with mild spinal disease compared to those with moderate-severe disease (p=0.046) – Figure 10. 
The lymphocyte ratio was significantly different based on the communicating nature of hydrocephalus 
(p<0.013), with the lowest ratio demonstrated in patients with communicating hydrocephalus – Figure 11. 
There were no other significant relationships with CSF ratios and radiology characteristics. 
 
Figure 10: Box and Whisker Plot for the Ratio of CSF Glucose Based on Spinal Disease Severity 
 
The box plot demonstrates the ratio of lumbar and ventricular glucose in patients with paired lumbar and ventricular 
CSF samples. Glucose for 32 CSF pairs were analysed. The ratio was calculated as lumbar/ventricular, and presented 
as a percentage. Mild spinal disease (n=4) was defined as a thin layer of exudate surrounding spinal cord and nerve 
roots, moderate as the presence of plaques or clumping of spinal nerve roots, and severe as the presence of extensive 
exudate in surrounding spinal cord and nerve roots or in subarachnoid space (moderate-severe spinal disease n=24). 
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Figure 11: Box and Whisker Plot for the Ratio of CSF Lymphocyte Count Based on the 
Communicating Nature of Hydrocephalus 
 
 
 
 
The box plot demonstrates the ratio of lumbar and ventricular glucose in patients with paired lumbar and ventricular 
CSF samples. Lymphocyte counts for 33 CSF pairs were analysed. The ratio was calculated as lumbar/ventricular, 
and presented as a percentage. Hydrocephalus was defined as communicating (n=20) if air was observed in the 
ventricular system after an air encephalogram, non-communicating (n=7) if air is observed at the base of the brain 
only, and uncertain (n=2) when the test could not be performed for patients in whom no CSF could be obtained through 
a lumbar puncture, or in patients for whom the test was not performed. 
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3.6 Analysis of association between morbidity, mortality and CSF lumbar and ventricular differentials 
and ratios 
Lymphocyte differential (p=0.04) and total white cell count differential (p=0.02) were significantly 
associated with favorable outcome in survivors. Box and whisker plots (Figure 12 and 13 respectively) of 
these findings are highlighted below. There were no other significant associations obtained. 
 
Figure 12: Box and Whisker Plot of CSF Lymphocyte Differential by Morbidity 
 
 
The box plot demonstrates the association between CSF lymphocyte differential and morbidity outcome in survivors. 
The differential was calculated as lumbar – ventricular CSF lymphocyte count. Lymphocyte count for 33 CSF pairs 
were analysed. Good outcome (n=16) is categorized as PCPCS score of 1-3. Unfavourable outcome (n=8) is 
categorized as PCPCS score of 4-5. 
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Figure 13: Box and Whisker Plot of CSF Total White Cell Count Differential by Morbidity 
 
 
 
The box plot demonstrates the association between CSF total white cell count differential and morbidity outcome in 
survivors. Total white cell count for 33 CSF pairs were analysed. The differential was calculated as lumbar – 
ventricular CSF total white cell count. Good outcome (n=16) is categorized as PCPCS score of 1-3. Unfavourable 
outcome (n=8) is categorized as PCPCS score of 4-5. 
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CHAPTER 4: DISCUSSION AND CONCLUSION 
 
4.1 Discussion 
This study examined ventricular and lumbar CSF in children with TBM in a pooled analysis of samples 
from 81 patients and in time-linked paired samples from 29 patients. Paired samples were examined to 
avoid any bias in the collection of pooled ventricular and lumbar CSF. In summary, the overall results show 
the persistent perturbations in CSF chemistry (glucose, chloride, protein) and cell count 
(polymorphonuclear cells, lymphocytes, total white cell count) in the first 3 weeks of TBM treatment in 
children with TBM and hydrocephalus. Across all parameters, lumbar CSF was significantly different to 
ventricular CSF, with derangements being more marked in the lumbar compartment. Lumbar CSF protein 
and white cell count typically were elevated and glucose and chloride were reduced. In contrast, ventricular 
CSF often only demonstrated mild disturbances. Analysis of pooled samples and of time-linked samples 
were similar. Knowledge of CSF trends and differences between compartments adds value for early 
diagnosis and treatment, as well as for clinical decision-making about surgical options for hydrocephalus 
treatment. Particularly where CSF biochemistry and cytology analytes diverge from traditionally expected 
patterns associated with TBM, or early in the presentation when TB microbiology results are not yet 
available, and empirical clinical decisions must be emergently instituted during routine clinical care to 
prevent possible TBM mortality/ morbidity. There are several implications of these findings: 1) If only 
ventricular CSF is available, it is important to note that it may demonstrate only mild features and this 
should not exclude the diagnosis of TBM. A lumbar CSF should be obtained when safe to do so; 2) For 
reporting and for clinical studies it is important that the compartment from which CSF is obtained is 
specified and that comparisons should only be done on samples from the same compartment; 3) For 
decisions about whether VP shunts are reasonable with reference to CSF protein values, the lumbar CSF 
does not reflect the ventricular CSF values and should not be used as a surrogate as such. 
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In the analysis of causative factors for the differences between the two compartments, the study is limited 
by smaller numbers of patients who had time-linked paired samples as well as MRIs; only 17 had full brain 
and spine MRIs in addition to time-linked paired samples. However, the results suggest some factors that 
need further exploration, in particular the nature of hydrocephalus and spinal disease, both of which may 
influence the flow of CSF between the ventricles and the spinal subarachnoid space. 
 
4.1.1 Clinical characteristics  
The results of patient demographics in this study are similar to those that have been reported by other TBM 
studies in the Western Cape (4,11,32,69). Patients typically are young and HIV positivity is low. Only 6 
patients in this study were HIV positive; the numbers were too small to analyse differences between the 
groups. Although the Western Cape is notorious for a high TB prevalence (82), only 37% of patients 
reported a TB contact. This low percentage may reflect caregiver under-reporting.  
In keeping with other studies (32,37,50), most patients presented late. The study cohort presented with 
advanced TBM disease and neurological deficits (MRC Stage 2 and 3). Most patients typically presented 
with nonspecific fever, weight loss, neck stiffness, depressed level of consciousness and focal neurology. 
Notably, our study reported higher proportions of confirmed Mtb in lumbar or ventricular CSF (43.2%) 
than reported in the literature (12%) (3). This may have been due to larger CSF volumes sent for analysis. 
Large volumes of CSF above 10ml are known to increase microbiological yield (5,57).  
 
The literature reports mortality in TBM ranging from 13-69% (12). This study demonstrated mortality rates 
on the lower end (13.6%), which is notable given the more advanced presentation of patients: almost 71.6% 
of the group were in Stage 2b or 3 at presentation, and 63% had brain infarction. The disease severity is 
consistent with the referral pattern to the hospital (the only dedicated paediatric intensive care and paediatric 
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neurocritical care hospital) and the presentation with hydrocephalus. Of interest, just over half the patients 
had documented high blood pressure for age and just under half had bradycardia, which may reflect a 
Cushing’s response to high ICP or brainstem ischemia. By 6 months, 77.5% patents had good neurological 
outcome (PCPCS). Several factors in the study setting could contribute to good neurological outcomes, 
including a well-resourced tertiary pediatric intensive care unit, early availability of MRI/CT scan, 
neurosurgical interventions, active in-hospital rehabilitation programs and possibly superior routine anti-
TBM drug therapy using Ethionamide which crosses blood brain barrier better than Ethambutol used 
elsewhere outside the Western Cape (5).  Of course, the PCPCS is a clinical score and does not take into 
account more subtle deficits that may affect neurodevelopmental outcomes. 
 
4.1.2 Lumbar and ventricular CSF compartments  
The study analysed the pooled differences between lumbar and ventricular CSF samples (n= 217 and 101 
respectively) as well as individual differences in time-linked paired samples in 29 patients. Overall, lumbar 
CSF results were typical of TBM patients, while ventricular CSF results were less abnormal. Broadly, 
protein and cells were significantly lower, and glucose and chloride higher in ventricular than in lumbar 
CSF. This highlights the relevance of interpreting CSF results in a context of the compartment from where 
it is drawn when attempting to fit results to existing diagnostic TBM criteria or interpreting various 
perturbations (4,68,75,82).  
 
Several possible reasons may explain the differences (6,16,85,32,40,45,69,70,78,79,81). First, tuberculous 
inflammation is more marked in the subarachnoid space of the basal cisterns than the ependyma of the 
ventricles. Given that the bulk flow theory of CSF flow is from ventricular space to subarachnoid space, 
and the spinal subarachnoid space is continuous with the cisterns of the brain, this may contribute to the 
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observed difference. Also, the main site of CSF production is in the ventricles so this may lead to a dilutional 
effect. Second, asymptomatic spinal disease (which was present in 80% of the unselected patients who 
underwent MRI) may contribute to the increased abnormalities in the lumbar CSF (16). Third, there is a 
physiological rostral-to-caudal differential in CSF biochemistry that may be exacerbated when there is a 
relative or absolute spinal block to CSF flow. A normal rostro-caudal CSF flow from ventricles to spinal 
subarachnoid space is described (86) triggered by the cardiac cycle (85). Lumbar CSF protein is subject to 
a cumulative effect of inflammatory proteins being added progressively as CSF flows caudally in the 
subarachnoid space by the addition of proteins due to the subarachnoid inflammatory process, particularly 
where there is spinal arachnoiditis, possibly caused by increased permeability of the inflamed lumbar 
meninges to blood-derived proteins and cells, and stagnation of CFS flow due to the relative block to CSF 
flow (78,79,85). Lower glucose in the lumbar space is suggested to represent cumulative glucose 
consumption along the rostro-caudal gradient and perturbed lumbar meningeal glucose transport as a result 
of local inflammation  (73,78,87). The features of spinal block in Froin’s syndrome are well described (76). 
The typical features of this are an overall increase in lumbar CSF protein, but specifically a decrease in 
brain-derived proteins with an increase in (predominant) blood-derived proteins, such as albumin (78) . 
This is consistent with the findings of the current study. In the study by Rohlwink et al. (88), the 
concentrations of brain-derived proteins such as S100B was higher in ventricular CSF, but concentrations 
of blood-derived proteins such as inflammatory mediators were higher in lumbar CSF. Albumin accounts 
for most of the protein in CSF and is blood-derived. The increased differential in cases of non-
communicating hydrocephalus and ‘uncertain’ hydrocephalus are also consistent with this: there is a block 
to CSF communication between the ventricles and the spinal subarachnoid space. The ‘uncertain’ 
hydrocephalus group likely reflects failure of air from the air encephalogram test to ascend through the 
spinal subarachnoid space due to arachnoiditis and exudate. This also would explain why the highest protein 
levels were found in this group.  
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Paired samples tended to be collected early after admission. CSF analyte patterns from unpaired 
independent ventricular and lumbar compartments showed widest differences during the first 1-2 weeks of 
admission upon attaining their peak or trough levels.  A similar pattern was expected within CSF pairs taken 
in the first week accounting for a wide analyte differential. Therefore, having a majority of CSF pairs drawn 
within the initial week of admission and a paucity of repeat CSF pairs over time was not expected to 
significantly affect study conclusions. 
 
4.1.2.1 CSF GLUCOSE 
Literature associates TBM with low CSF glucose <2.2 mmol/L (82), classically in reference to lumbar CSF. 
This study showed that lumbar and ventricular CSF glucose profiles distinctly differed overall and across 
time. The median differential between lumbar and ventricular CSF glucose was -1.9 mmol/L in paired 
samples. A delay in normalization of lumbar CSF glucose is described in fully and partially treated 
populations (69–71). In this study, lumbar CSF glucose was initially decreased as expected and normalized 
in the second week. In contrast, ventricular CSF glucose remained within normal limits most of the time 
(94%) and was higher than lumbar CSF glucose in 94% of cases. 
 
4.1.2.2 CSF CHLORIDE 
There are few studies on chloride in paediatric TBM. Ramkissoon & Coovadia (89) identified an association 
between low CSF chloride (less than 110 mmol/L) and TBM, provided bacterial meningitis was excluded.  
Rohlwink et al. commented on RCWMCH TBM clinical diagnostic criteria, which includes CSF chloride 
less than 116 mmol/L (32). Our study also used a normal CSF chloride lower limit of 116 mmol/L for both 
compartments in keeping with standard pediatric text values (83). Interestingly, CSF chloride is not 
included as a parameter in the globally accepted TBM diagnostic criteria (4,68). Ventricular CSF chloride 
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was low only on admission and then normalized whereas lumbar CSF chloride remained low. Chloride was 
lower in lumbar than ventricular CSF in almost 75% of the paired cases. 
4.1.2.3 CSF PROTEIN 
For pooled and time-linked samples, the median protein concentration was lumbar CSF was 2g/L and for 
ventricular CSF 0.5 g/L. Regardless of the threshold used, lumbar CSF protein was consistently higher. For 
paired samples, all of the lumbar CSF results showed an abnormally high protein (based on the higher 
threshold of 0.8g/L), whereas only 22% of ventricular CSF samples showed elevated protein. The median 
difference between lumbar and ventricular CSF protein concentrations in individual paired cases was 1.5 
g/L (IQR 1.1 to 2.8 g/L). These results are contrary to the results of Kamat et al. who found equivalent 
concentrations of protein in ventricular and lumbar CSF (77). In their study, CSF protein was remarkably 
similar in ventricular and lumbar CSF samples (2.471g/L and 2.474g/L respectively). The authors suggest 
that lumbar CSF protein levels can be used to predict ventricular CSF protein, the level of which should be 
a guide to whether a shunt should be placed or not, given their observation that patients with higher protein 
levels had an increased risk of shunt blockage. However, there are several potential limitations and possible 
explanations of their data. Only mean values were reported; when reporting on the same paediatric cohort 
of the patients at the same institution, Van Well (3) reported a much lower median concentration of protein 
(1.6 g/L). Also, the analysis was only done on pooled samples, which may mask the true differences 
between ventricular and lumbar samples in individual patients. Further clarity is needed on the subject 
because studies of protein levels in CSF point to a clear differential between ventricular and lumbar CSF 
and the known physiological and pathological factors that may influence this (78,79). There are important 
implications to this – access to ventricular CSF is not standard and so in most patients lumbar CSF studies 
are used as a proxy for diagnosing and interpreting brain pathological processes, and in some cases directing 
therapies including surgery. Based on our results, this should be done with caution. 
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Protein levels in the lumbar CSF slowly decreased from the second week, but in general remained elevated. 
All study patients received standard steroid-containing TBM therapy expected to yield normalization of 
protein across all CSF compartments (32,69,70). We demonstrated steady lumbar protein decline, 
approaching normal during days 17-21. It is difficult to comment on the temporal profile of ventricular CSF 
values beyond the first two weeks because the numbers are small and may reflect bias from patients with 
ongoing disease processes including unresolved hydrocephalus. Neurosurgical interventions (EVD, VPS) 
were unlikely to contribute to persistent raised ventricular CSF protein because CSF derangements 
immediately post-neurosurgical interventions were excluded and any concomitant bacterial meningitis was 
ruled out.  
 
4.1.2.4 CSF WHITE CELLS 
The study results concurred with literature descriptions of elevated CSF white cells with lymphocyte 
predominance (4,32,68,82), particularly in the lumbar CSF compartment. Ventricular white cells were 
markedly less than the lumbar compartment, only mildly elevated with the highest values on admission. 
White cell concentrations were 170 x106/L (lumbar CSF) versus 15 (ventricular CSF) for pooled samples 
and 202 versus 23 for paired samples. The difference between the compartments may be due to a greater 
inflammatory process occurring in the subarachnoid space or the influence of spinal disease, as discussed 
above. Although there was a progressive decrease over time (late in the first week), white cells remained 
elevated and failed to normalise by day 21 in both lumbar and ventricular compartments. The persistent 
elevation of white cells may be clinically useful in diagnosing paediatric TBM particularly in the context 
of repeated CSF sampling after 2-3 weeks. This study also demonstrates that TBM should not be excluded 
based on normal to mildly raised polymorphonuclear cells or lymphocytes in ventricular CSF. Over time, 
there was a slight increase in cells and protein in the ventricular CSF samples. This reflects a small number 
of samples from patients (n=3) who likely do not reflect the average (and therefore required external 
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ventricular drainage and/ or ventricular shunts which enabled access to ventricular CSF). This is also seen 
in lumbar CSF polymorphonuclear cell count in the third week. We excluded patients with any obvious 
bacterial infection as a consequence of the external ventricular drain, but it is possible that these patients 
reflect outliers or a cellular reaction to a persistent external ventricular drain. Regardless, these small 
numbers late in the disease course probably do not reflect a typical pattern in TBM. 
 
4.1.3 Lumbar and ventricular CSF analytes, radiology and factors influencing CSF differentials 
4.1.3.1 RADIOLOGY FINDINGS IN TBM WITH HYDROCEPHALUS 
With respect to the level of CSF obstruction, 16% had non-communicating hydrocephalus, consistent with 
previously published results; 11% had an uncertain level of obstruction. The latter was the result of a strict 
definition and reflects failure to demonstrate air in cranium in the air encephalography study. Strictly 
speaking, this cannot be described as non-communicating and must be due to a technical failure or because 
of an obstruction to CSF in the spinal canal. Although the numbers are small, the highest protein levels are 
seen in this group, in keeping with the possibility that this reflects a spinal block. Five of the nine patients 
with uncertain hydrocephalus had spinal imaging, and all of them showed evidence of spinal disease. In 
keeping with this, maximum lumbar CSF protein was significantly associated with the severity of spinal 
disease on imaging. Rohlwink  et al.  (16) also demonstrated that spinal exudate is associated with higher 
lumbar CSF protein and can cause near or complete obliteration of the thecal sac. In an open system, the 
rostro-caudal CSF flow (86) may facilitate an equilibration of biochemical analytes and leukocytes and, 
consequently, less difference between the ventricular and lumbar compartments. In these cases, the high 
concentration of protein in the spinal canal likely represents an accumulation of inflammatory exudate and 
a stagnation of CSF flow. This likely contributes to a dry tap and inability to perform the AEG or column 
test, and could hinder the course of air up the spinal canal if the AEG could be performed, leading to an 
uncertain result. Consistent with this, the lymphocyte ratio between lumbar and ventricular CSF was also 
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higher in patients with non-communicating and uncertain hydrocephalus. In these situations (very high 
lumbar CSF protein and marked differences between lumbar and ventricular CSF results), rational use of 
MRI spine may be indicated. Inability to obtain lumbar CSF (possibly due to very high protein 
concentrations) should raise suspicion of spinal arachnoiditis, tuberculoma or exudate. 
 
With respect to brain imaging, typical radiological findings were demonstrated (16,18,22,50,90). The 
results showed almost universal basal meningeal enhancement on contrasted CT brain (97.4%), although it 
was scored as mild in almost half of admission scans. This highlights the need for routine use of contrast in 
the radiological diagnosis of TBM and importance of a trained radiologist eye to detect mild radiological 
changes. Brain infarcts (63%) and brain tuberculomas (47.4%) were common but sometimes occurred on 
subsequent scans over time. This emphasises the value of access to repeat diagnostic brain imaging in 
endemic areas, which are unfortunately often the poorest resourced.  The development of disease 
manifestations over time is also consistent with the persistent protein and white cell perturbations found in 
lumbar and ventricular CSF, reflecting an ongoing inflammatory process despite commencement of TBM 
treatment. 
 
4.1.4 Lumbar and ventricular CSF analyte association with morbidity and mortality 
In our results, patients with a favorable outcome had a greater differential between lumbar and ventricular 
CSF for lymphocytes and total white cell count. The reason for this is not apparent as a similar association 
was not found for differentials of other parameters. Therefore, this may be a spurious result, a reflection of 
higher white cell counts in ventricular CSF, or a proxy for differences in the way patients were treated if a 
CSF block was suspected. Patterns of host intracranial inflammatory response in TBM may play a role. In 
view of a dearth of literature on the subject, further research is required to confirm this finding.  
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4.1.5 Limitations 
Completeness of demographic, clinical and outcome data was influenced by quality and detail of clinical 
notes documented by attending doctors. However, it did not have a substantial effect on the quality or 
completeness of laboratory CSF data, which was the study’s primary focus. Although various data sources 
were interrogated to identify patients, a few patients may have been missed due to poor record keeping and 
patient notification.  
 
Many TBM patients do not receive follow up at RCWMCH after discharge on TBM treatment but are 
referred to secondary level hospitals. Data on serial CSF samples, therefore, was limited to patients with 
clinical follow up and repeat CSF studies done at RCWMCH. Similarly, outcome data was limited to 
patients who were followed up at RCWMCH, and collection of secondary data to assign a PCPCS score 
was tied to the quality and completeness of clinical notes recorded by the attending doctor. There was a 
likelihood of bias from patients lost-to-follow-up which could affect serial sampling and outcome. The 
researchers aimed to look at association of outcome, the small sample size is acknowledged. There would 
be benefit conducting more studies in future based on a larger sample size. 
 
 
As this study analysed samples taken as part of routine clinical care, the timing of serial CSF lumbar and/ 
or ventricular samples sent for laboratory analysis did not follow a prescribed interval. CSF samples were 
collected at the discretion of the attending doctor in line with the patient’s clinical progress and condition. 
The trend analysis was therefore biased by different numbers of CSF samples available at the different time 
points. However, as all of these patients had hydrocephalus, we were able to examine several samples in 
each patient over the 3-week period. Similarly, tracking functional neurological outcome using the PCPCS 
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score (Appendix 6) could only be done based on when patients were routinely followed up which did not 
follow a strict pre-set time protocol. Samples for analysis were biased towards those patients who survived 
the acute stages of TBM, therefore this study was limited to patients who survived. 
 
Spinal imaging was performed in less than half the study group, preventing full examination of the impact 
of spinal disease on CSF parameters and the differential between compartments. Spinal imaging in TBM is 
not a routine part of investigative protocols, but was rather the focus of one of the existing studies. Not all 
patients had MRI brain and spine given that CT imaging is standard for admission imaging and those 
patients who died early did not receive follow up MRI imaging. Furthermore, there were only 6 patients 
with severe spinal disease. In patients with the most severe spinal disease, it was often not possible to obtain 
CSF. 
 
Finally, these data apply to children, adult CSF characteristics may differ: typically, slower CSF flow rates 
with age correspond to physiologically higher protein concentrations. 
 
 
4.2 Conclusion and Recommendations   
This study illustrated that CSF chemistry and cell count differ between the ventricular (rostral) and lumbar 
(caudal) compartments in TBM with hydrocephalus across time. Importantly, the data highlights the fact 
that: 1) lumbar and ventricular CSF in TBM are significantly different; 2) ventricular CSF may not 
demonstrate the typical picture of perturbed CSF expected in TBM, that this should not dismiss suspicions 
of TBM, and that the CSF compartment of sampling must be taken into account when diagnosing TBM; 3) 
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spinal disease, and the level of CSF block causing hydrocephalus, may influence the ability to sample 
lumbar CSF and the analyte concentrations in the lumbar CSF. In addition to the impact on clinical 
decisions, these differences should also be considered in studies usually based on lumbar CSF, including 
diagnostics, disease biomarkers or drug recovery. Further clinical utilization of these results and 
determination of reasons for the differences require additional research. 
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APPENDICES 
 
Appendix 1: Revised Medical Research Council (MRC) Scale for Staging TBM (37) 
 
TBM Stage Clinical Criteria 
1 GCS 15, patient alert and oriented with no focal neurological deficits 
2a GCS 15, patient alert and oriented but with neurological deficit; OR 
GCS 13-14 with/ without neurological deficit 
2b GCS 10-12 with/ without focal neurological deficits 
3 GCS < 10 with/ without focal neurological deficits 
 *GCS = Glasgow Coma Scale 
Adapted from van Toorn, R., Springer, P., Laubscher, J. & Schoeman, J. 2012. Value of different staging systems for 
predicting neurological outcome in childhood tuberculous meningitis. International Journal of Tuberculous Lung 
Disease. 16(5):628-632. 
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Appendix 2: Consensus Case Definition of TBM 
a) Table 1: TBM Case Definition Classification,  TBM Case Definition in Research Settings, 
(4) 
TBM CASE DEFINITION 
CLASSIFICATION 
SUMMARY OF COMPONENTS 
Definite TBM Isolation of Mtb in CSF (AFB/ culture/ DNA PCR); histopathological 
diagnosis 
Probable TBM Higher diagnostic score with or without brain imaging plus exclusion of 
alternative diagnosis 
Possible TBM Lower diagnostic score with or without brain imaging plus exclusion of 
alternative diagnosis; CSF or brain imaging required 
Not TBM Alternative diagnosis established and absence of co-morbidity with TBM 
  
Clinical entry criteria Headache, irritability, vomiting, fever, neck stiffness, convulsions, focal 
neurological deficits, altered level of consciousness, lethargy 
Adapted from Marais, S., Thwaites, G., Schoeman, J., Torok, M., Misra, U., Prasad, K., Donald, P., Wilkinson, R. et 
al. 2010. Tuberculous meningitis: A uniform case definition for use in clinical research. Lancet. (10):803-812. 
DOI:10.1016/S1473-3099(10)70138-9. 
 
 
 
b) Table 2: Scoring Table, TBM Case Definition in Research Settings, (4) 
 CRITERIA DIAGNOSTIC SCORE 
1 Clinical Criteria Maximum category score = 6 
  Symptom duration > 5 days; 
 Systemic symptoms suggestive of TB – one or more of: 
Weight loss; night sweats; cough > 2 weeks; 
 In children < 10yrs old, history of recent (< 1yr) close 
contact with person diagnosed positive pulmonary TB/ 
positive TST/ positive IGRA; 
 Focal neurological deficit (excluding cranial nerve 
palsies); 
4 
2 
 
2 
 
 
1 
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 Cranial nerve palsies 
 Altered level of consciousness 
 
1 
1 
   
2 CSF Criteria Maximum category score = 4 
  Clear appearance; 
 10-500 x106/L; 
 Lymphocyte predominance > 50%; 
 Protein level > 1g/L; 
 CSF:Plasma glucose ratio < 50% OR an absolute CSF 
glucose < 2.2 mmol/L 
1 
1 
1 
1 
1 
   
3 Cerebral Imaging Criteria Maximum category score = 6 
  Hydrocephalus; 
 Basal meningeal enhancement; 
 Tuberculoma; 
 Infarct; 
 Pre-contrast basal hyperdensity 
1 
2 
2 
1 
2 
   
4 Evidence of TB elsewhere Maximum category score = 4 
  CXR suggestive of active TB where signs of TB = 2, 
miliary TB = 4 
 CT/ MRI/ Ultra sound evidence of TB outside the CNS 
 Positive AFB seen OR Mtb cultured from another 
source i.e. Sputum, lymph node, gastric washings, 
urine, blood culture 
 Positive commercial Mtb NAAT from an extra neural 
specimen 
2 OR 4 
 
2 
4 
 
 
4 
   
5 Exclusion of Alternative Diagnosis  
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  An alternative diagnosis must be confirmed via 
microbiology, serology or histopathology 
 Consider alternative diagnosis (depending on age, 
immunological status, geographic region) e.g. CNS 
infections (bacterial, viral, parasitic e.g. cerebral malaria 
or opportunistic infections), brain abscess and CNS 
malignancy 
 
 Abbreviations: AFB – Acid Fast Bacilli; CNS – Central Nervous 
System; CSF- Cerebrospinal Fluid; CT - Computer Tomography 
Scan; IGRA- Interferon-Gamma Release Assays; TB – 
Tuberculosis; TST – Tuberculin Skin Test; MRI – Magnetic 
Resonance Imaging; Mtb – Mycobacterium tuberculosis; NAAT – 
Nucleic Acid Amplification Test 
 
Adapted from Marais, S., Thwaites, G., Schoeman, J., Torok, M., Misra, U., Prasad, K., Donald, P., Wilkinson, R. et 
al. 2010. Tuberculous meningitis: A uniform case definition for use in clinical research. Lancet. (10):803-812. 
DOI:10.1016/S1473-3099(10)70138-9. 
 
  
94 
 
Appendix 3: Parameters for Treating TBM at RCWMCH 
PARAMETER EXPECTED YIELD 
HISTORY   
Constitutional symptoms of TB – fever, weight loss, night sweats, loss of appetite  
History of a recent TB contact. (Investigate contact’s TB information)  
History of positive Mantoux  
Growth faltering/ crossing weight centiles on Road to Health Card  
PHYSICAL EXAMINATION  
Wasting, lymphadenopathy  
Clinical features of TB elsewhere e.g. pulmonary TB, abdominal TB, TB adenitis  
Features consistent with Meningitis  
Clinical findings in keeping with the classification of stage 1, 2 and 3 TBM 
STAGE 1 – meningitis, no neurological fallout, no depression of level of consciousness 
STAGE 2 – depressed level of consciousness, cranial nerve fallout, seizures 
STAGE 3 – comatose 
 
  
LABORATORY  
CSF (lumbar CSF and where hydrocephalus present ventricular CSF) 
Cytology (hours) – moderately raised white cells with a lymphocyte predominance,  
Biochemistry (hours) - low glucose, markedly high protein, low chloride 
 
Microbiology – evidence of Mtb in CSF  
a) Standard practice: acid fast bacilli on Ziehl-Neelsen stain - hours; TB culture – up 
to 42 days  
b) Selected cases at doctor’s discretion: TB PCR Cephin Gene Xpert – days 
40% (Schoeman, 
2001) 
 
Use of Gene Xpert not 
yet validated on CSF 
and is not yet standard 
practice.  
TBM with no hydrocephalus: Repeat lumbar CSF study 3 - 4 weeks later looking for 
persistent CSF changes which points towards a likely diagnosis of TBM (assessment and 
decision made by pediatrician team with/ without consultation with neurosurgeons) 
 
TBM with hydrocephalus requiring neurosurgical decompression interventions (e.g. 
Endoscopic Third Ventriculostomy, Ventroperitoneal Shunt) or conservative medical 
management with Acetazolamide and Lasix: Repeat ventricular CSF at intervals 
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determined by neurosurgeons and clinical condition of the patient (assessment and 
decision made by neurosurgeons) 
  
RADIOLOGY SUGGESTIVE OF TBM  
Uncontrasted & contrasted CT brain (up to 24 hours) – basal meningeal enhancement; 
acute hydrocephalus; tuberculomas 
83% (Schoeman 2001) 
  
SUPPORTIVE INVESTIGATIONS  
Chest X-Ray suggestive of Pulmonary TB 60% (Schoeman 2001) 
Positive Mantoux (72hrs) 65% (Schoeman 2001) 
Induced sputum (days for microscopy and Ziehl-Neelsen stain, weeks for culture and 
Cephin Gene Xpert) 
 
Gastric washings (days for microscopy and Ziehl-Neelsen stain, weeks for culture and 
Cephin Gene Xpert) 
40% (Schoeman 2001) 
Blood – raised Erythrocyte Sedimentation Rate; wide globulin fraction  
Ultrasound of abdomen (days to week)  
Fine Needle Aspiration Biopsy of suspected TB lymph node (days for histology and 
microbiology for Ziehl-Neelsen stain) 
 
Source: Author and Co-Authors Personal Experience and Practice Protocols at RCWMCH 
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Appendix 4: Treatment Algorithm for Raised Intracranial Pressure in Pediatric TBM with 
Hydrocephalus (34) 
 
 
 
 
 
 
 
 
  
Pediatric TBM 
Communicating 
Hydrocephalus 
Non-communicating 
Hydrocephalus 
Medical Management: 
 
Monitor CSF pressure 
Serial Lumbar Punctures 
Pharmacothrapy (Frusemide, 
Acetazolamide) 
EVD or VPS 
VPS 
EVD 
Severe depressed level 
of consciousness 
Communicating 
hydrocephalus 
Non- 
communicating 
Hydrocephalus 
Medical 
Management 
ETV 
VPS VPS 
CT Brain 
AEG or contrast ventriculography 
Failed after 3 weeks 
CT Brain 
CT Brain 
AEG or contrast ventriculography 
Failed Mx. 
*ETV-Endoscopic Third Ventriculostomy; EVD-External Ventricular Drain; TBM-Tuberculous Meningitis; VPS-Ventriculo-Peritoneal Shunt 
(Adapted from Figaji, A., Fieggen, A. & Peter, J. 2003. Endoscopic third ventriculostomy in tuberculous meningitis. Child’s Nervous System. 19:217-
225)  
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Appendix 5: Brain/ Spinal Imaging Grading Criteria RCWMCH 
a) Table 1: Description of Brain Imaging (with Contrast) Parameters in TBM with 
Hydrocephalus 
 CT Brain Imaging Parameter Definition and Grading 
1 Basal meningeal 
enhancement 
Focal: enhancement localised 
Diffuse: enhancement not localised 
2 Hydrocephalus  Mild: rounding of 3rd ventricle, visible temporal horns 
Moderate: all ventricles dilated, absence of transepyndymal fluid shift 
Severe: transepyndymal fluid shift, ventricles dilated, loss of sulcal 
markings 
3 Pre-contrast 
hyperdensity 
Assessed on uncontrasted CT brain scan. Sylvian fissures or basal cisterns 
hyperdense and obliterated 
4 Tuberculomas and TB 
abscess 
Number: single or multiple 
Anatomical location 
Unilateral Vs bilateral occurrence 
5 Infarcts  Number: single or multiple 
Size: small - lacunar infarcts 
Medium - multiple or large size 
Global - extensive infarction present in all vascular regions 
Source: Adapted from RCWMCH Radiology Department (2015)  
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b) Table 2: Description of MRI Spinal Imaging (With Contrast) Parameters in TBM and 
Hydrocephalus 
 
 Spinal Imaging Parameter Definition and Grading 
1 Spinal Arachnoiditis  Definition: Contrast enhancement of spinal roots or spinal cord. Presence of 
intradural or extra-dural exudate collections (plaques), nodules, clumping of 
spinal nerve roots was assessed. 
Grading: Mild - thin layer of exudate surrounding spinal cord and nerve 
roots 
Moderate - presence of plaques or clumping of spinal nerve roots 
Severe - presence of extensive exudate in surrounding spinal cord and nerve 
roots or in subarachnoid space 
2 Tuberculomas or TB 
abscesses 
Divided into two anatomical categories namely intra-medullary or surface 
Source: Adapted from RCWMCH Radiology Department (2015)  
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Appendix 6: Pediatric Cerebral Performance Cognitive Scale [PCPCS], (84)  
 
Clinical Features Category Score 
Normal at age appropriate level;       
School age child attends regular school classroom 
Normal 1 
Conscious alert and able to interact at an age appropriate 
level;                                              
School age child attending regular school classroom but 
grade perhaps not appropriate for age;                                        
May have a mild neurologic deficit 
Mild disability 2 
Conscious;     
Sufficient cerebral function for age-appropriate independent 
activities of daily life;                                                                         
School age child attending special education classroom;  
may have learning deficit 
Moderate disability 3 
Conscious;                                                               
Dependent on others for daily support because of impaired 
brain function 
Severe disability 4 
Any degree of coma without any of the criteria for brain 
death;                                     
Unawareness even if awake in appearance without 
interaction with the environment;     
Cerebral unresponsiveness;                                    
No evidence of cortical function and not aroused by verbal 
stimuli;                                       
Possibly some reflexive responses spontaneous eye opening 
and/ or sleep-wake cycles 
Coma/ vegetative state 5 
Apnea; OR                                                                    
Areflexia; OR                                                               
electroencephalographic (EEG) silence 
Brain death 6 
Adapted from Fiser, D. 1992. Assessing the outcome of pediatric intensive care. Journal of Pediatrics. 121(1):68-74 
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Appendix 7: TB Contacts In Study Patients Treated for TBM with Hydrocephalus at RCWMCH 
 
 
 
 
Graph showing known TB contacts. Blue bars represent absolute number. Red bars represent percentage. 
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Appendix 8:  Sites of TB Outside the CNS 
 
One third patients (n=29, 36%) had co-existing clinical features of TB outside the nervous system. Twenty 
five (30.86%) demonstrated radiological evidence of PTB and 2 (2.47%) of TB abdomen. One patient 
(1.23%) had TB disseminated to both the lung and abdomen. 
 
 
 
Sites of TB outside the central nervous system. Blue bar represents absolute number, orange bar represents percentage. 
PTB = pulmonary TB, TB = tuberculosis 
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Appendix 9: Profiles of Lumbar and Ventricular CSF Parameters timepoints day 17-21 
 
Pt No. 
Day of 
collection Location 
Glucose 
(mmol/L) 
protein 
value 
(g/L) 
Chloride 
(g/L) 
Polymorphonucle
ar cells 
(x106/L) 
Lymphocyte
s (x106/L) 
TWCC 
(x106/L) 
27 18 2 2,4 1,42 124 1 36 37 
44 20 2 2,5 2,09 118 10 93 103 
70 17 2 2,1 2 115 3 98 101 
73 19 2 3,2 0,92 118 0 136 136 
3 20 1 3,1 0,23 121 0 29 29 
5 16 1 2,6 2,55 111 50 135 185 
5 21 1 2,6 3,25 112 14 73 87 
6 17 1 2,9 0,61 120 17 20 37 
9 19 1 3,5 0,49 136 1 61 62 
9 21 1 3,1 0,77 143 0 71 71 
11 19 1 2,8 6,13 114 0 68 68 
13 20 1 1,2 2,22 110 20 270 290 
21 21 1 3,2 2,25 116 405 170 575 
23 19 1 3,2 0,38 116 8 87 95 
25 17 1 2,9 1,02 119 41 21 62 
25 19 1 1,2 3,32 113 99 268 367 
30 17 1 2,6 1,1 128 3 125 128 
31 19 1 3,6 1,34 172 11 39 50 
32 18 1 3,6 0,91 129 21 52 73 
33 17 1 2,7 2,16 122 2 85 87 
36 18 1 4,4 2,31 101 3 20 23 
37 21 1 1,5 1,62 112 46 65 111 
55 18 1 1,9 2 121 2 63 65 
59 18 1 3 2 115 49 100 149 
68 17 1 2,5 2 129 5 156 161 
71 18 1 2,7 0,78 118 4 66 70 
72 17 1 2,3 0,93 124 15 41 56 
73 18 1 2,5 1,05 119 2 202 204 
77 18 1 1,8 3 109 62 78 140 
78 18 1 3 1 126 4 20 24 
The table illustrates CSF datapoints excluded from analysis due to small sample numbers taken post-admission on day 17-
21 time epoch. Under the column “location”: 1=Lumbar CSF. 2=Ventricular CSF. 
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Appendix 11: Red Cross War Memorial Hospital Research Approval Letter 
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Appendix 12: Study Data Collection Tool 
A Sheet 1 - TBM Cases, Clinical Notes Clinical Data Variables: Response (code) 
DEMOGRAPHICS 
1 Ref code 
2 Patient Name (First name, Surname) 
3 Folder number 
4 Date of Birth (dd/mm/yyyy) 
5 Age (in months) 
6 Gender Male (1)  Female (2) 
7 Admission date (dd/mm/yyyy) 
HIV AND NUTRITION STATUS 
8 HIV status Positive (1)  Negative (0)  Unknown (3) 
9 If HIV positive, is patient on HAART Yes on HAART (1)  No not yet on HAART (0) 
10 Nutritional status 
Normal weight for age, >/= -1SD (1) 
Malnourished, < -1SD (0)      
Not recorded (9) 
11 Other co-morbid disease Yes (1)  No (0)  Not stated (2) 
TB INFORMATION 
12 
TBM diagnosis (Marais et al. (4) definition) Definite TBM (1) 
Probable TBM (2) 
No TBM (3) 
Not recorded (9) 
13 Known TB Contact Yes (1)  No (0) 
14 List who is the known TB contact 
CONSTITUTIONAL SYMPTOMS 
15 Any constitutional symptoms Yes (1)  No (0)  Not stated (2) 
16 Fever Yes (1)  No (0)  Not stated (2) 
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17 Weight loss Yes (1)  No (0)  Not stated (2) 
18 Night sweats Yes (1)  No (0)  Not stated (2) 
19 Cough Yes (1)  No (0)  Not stated (2) 
20 Mantoux result Positive (1)  Negative (0)  Not done (2) 
21 TB elsewhere (outside of CNS) Yes (1)  No (0)  Not stated (2) 
22 
List other sites of TB infection outside CNS, 
Date and results of investigations done 
Pulmonary TB (1) 
TB abdomen (2) 
Other site: state (4) 
TBM IMAGING 
23 Brain imaging done Yes (1)  No (0)  Not stated (2) 
24 
Type of brain/ spinal imaging done CT brain/ spine (1) 
MRI brain/ spine (2) 
Both CT and MRI brain/spine (3) 
25 
Brain imaging results and date (dd/mm/yyyy) Hydrocephalus (yes, no) 
Hydrocephalus severity (mild, moderate, severe) 
Meningeal enhancement (yes, no) 
Tuberculoma or TB abscess (yes, no) 
Number of tuberculoma/ TB abscess (single, multiple) 
Infarcts (yes, no) 
Number of infarcts (single, multiple) 
Spinal arachnoiditis (yes, no) 
Severity of arachnoiditis (mild, moderate, severe) 
26 
TBM diagnosis (Marais et al. (4) definition) Definite TBM (1) 
Probable TBM (2) 
No TBM (3) 
Not recorded (9) 
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HYDROCEPHALUS INFORMATION 
27 Hydrocephalus Yes (1)  No (0)  Undefined (9) 
28 
Type of hydrocephalus Communicating (1) 
Non-communicating (0) 
Undefined (failed test/ unspecified) (9) 
29 
Air encephalogram result Communicating HCP (1) 
Non-communicating HCP (2) 
Failed test (5) 
Not done (9) 
30 
Air encephalogram date, (dd/mm/yyyy) Communicating HCP (1) 
Non-communicating HCP (2) 
Failed test (5) 
Not done (9) 
31 
Column test result Communicating HCP (1) 
Non-communicating HCP (2) 
Failed test (5) 
Not done (9) 
32 Column test date, (dd/mm/yyyy) 
TBM STAGING AND FOCAL 
NEUROLOGICAL SIGNS 
33 
Revised MRC TBM Staging – (van Toorn et al. 
(37) )
Stage 1 (GCS 15 without focal neurology) 
Stage 2a (GCS 15 with neurological deficit/ GCS13-14 with/without 
neurological deficit) 
Stage 2b (GCS 10-12 with/without focal neurological deficit) 
Stage 3 (GCS < 10 with/without neurological deficit) 
34 Focal neurological signs Yes (1)  No (0)  Not stated (2) 
35 
Pupils Bilaterally reactive (1) 
Unilaterally non-reactive (2) 
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Bilaterally not reactive (3) 
Sluggish (4) 
Not stated (9) 
36 
Paresis No paresis (1) 
Hemiparesis (2) 
Quadriparesis (3) 
Not stated (9) 
37 Raised intracranial pressure Yes (1)  No (0)  Not stated (2) 
38 Raised blood pressure Yes (1)  No (0)  Not stated (2) 
39 Bradycardia Yes (1)  No (0)  Not stated (2) 
40 Headache Yes (1)  No (0)  Not stated (2) 
41 Irritability Yes (1)  No (0)  Not stated (2) 
42 Vomiting Yes (1)  No (0)  Not stated (2) 
43 Neck stiffness Yes (1)  No (0)  Not stated (2) 
44 Seizures Yes (1)  No (0)  Not stated (2) 
45 Abnormal posturing Yes (1)  No (0)  Not stated (2) 
46 
Altered level of consciousness (Glasgow Coma 
Scale <15) 
Yes (1)  No (0)  Not stated (2) 
47 Lethargy Yes (1)  No (0)  Not stated (2) 
48 Not walking Yes (1)  No (0)  Not stated (2) 
49 Bulging anterior fontanelle Yes (1)  No (0)  Not stated (2) 
50 Papilledema Yes (1)  No (0)  Not stated (2) 
51 Sun-setting eyes Yes (1)  No (0)  Not stated (2) 
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B Sheet 2 - CSF Results, NHLS Response: value, units 
1 Ref code 
2 Patient Name (First name, Surname) 
3 Folder No. 
52 Date of CSF sample (dd/mm/yyyy) 
53 Time of CSF sample (hr/ min) 
54 CSF sample site 
Lumbar puncture (1) 
Ventricular compartment (2) 
55 CSF Appearance 
Clear & colorless 
Turbid 
Xanthrochromic 
Blood stained 
CSF BIOCHEMISTRY RESULTS 
56 Glucose measurement  mmol/L 
57  Lower glucose limit Glucose </= 2.2 mmol/L;    Yes (1)  No (0) 
58 Protein measurement  g/dL 
59  Upper protein limit 
Protein > 0.4 g/L      Yes (1)  No (0) 
Protein > 0.8 g/L      Yes (1)  No (0) 
Protein > 1 g/L  Yes (1)      No (0) 
60 Chloride measurement  mmol/L 
61  Lower chloride limit Chloride < 116 mmol/L     Yes (1)    No (0) 
CSF CYTOLOGY RESULTS 
62 Polymorphonuclear cell count  x106/L 
63  Upper polymorph limit Polymorph > 0 x106/L    Yes (1)    No (0) 
64 Lymphocyte count  x106/L 
65  Upper lymph limit Lymph >5  x106/L  Yes (1)    No (0) 
66 Total White Cell count  x106/L 
111 
67  Upper TWCC limit TWCC > 10 x106/L     Yes (1)   No (0) 
CSF MICROBIOLOGY RESULTS 
68 Gram stain Positive (1)  Negative (0)  Not done (9) 
69 Bacterial culture Positive (1)  Negative (0)  Not done (9) 
70 CSF Ziehl-Neelsen Stain (AFB) 
Positive AFB (1) 
Negative AFB (2) 
Not done (9) 
71 TB culture 
Positive (1) 
Negative (2) 
Not done (9) 
72 TB PCR GeneXpert 
Positive (1) 
Negative (0) 
Not done (9) 
C Sheet 3 - Outcome Data: morbidity in 
survivors; and mortality 
Response (code) 
1 Ref code 
2 Patient Name (First name, Surname) 
3 Folder number 
73 Mortality Alive (1);  date (dd/mm/yyyy) 
Dead (0);  date (dd/mm/yyyy) 
74 Morbidity in survivors (Pediatric Cerebral 
Performance Cognitive Scale) 
Normal (1) 
Mild disability (2) 
Moderate disability (3) 
Severe disability (4) 
Coma/ Vegetative state (5) 
Brain dead (6) 
